Document:

exv10w20

 

Exhibit 10.20

MannKind Corporation

2004 Non-Employee Directors’ Stock Option Plan

Adopted March 23, 2004

Approved by Stockholders March 23, 2004

Effective Date: August 2, 2004

1. Purposes.

     (a) Eligible Option Recipients. The persons eligible to receive Options are the Non-Employee
Directors of the Company.

     (b) Available Options. The purpose of the Plan is to provide a means by which Non-Employee
Directors may be given an opportunity to benefit from increases in value of the Common Stock
through the granting of Nonstatutory Stock Options.

     (c) General Purpose. The Company, by means of the Plan, seeks to retain the services of its
current Non-Employee Directors, to secure and retain the services of new Non-Employee Directors and
to provide incentives for such persons to exert maximum efforts for the success of the Company and
its Affiliates.

2. Definitions.

     (a) “Affiliate” means any parent corporation or subsidiary corporation of the Company, whether
now or hereafter existing, as those terms are defined in Sections 424(e) and (f), respectively, of
the Code.

     (b) “Annual Grant” means an Option granted annually to all Non-Employee Directors who meet the
specified criteria pursuant to Section 6(b).

     (c) “Annual Meeting” means the annual meeting of the stockholders of the Company.

     (d) “Board” means the Board of Directors of the Company.

     (e) “Capitalization Adjustment” has the meaning ascribed to that term in Section 11(a).

     (f) “Code” means the Internal Revenue Code of 1986, as amended.

     (g) “Committee” means a committee of one or more members of the Board appointed by the Board
in accordance with Section 3(c).

     (h) “Committee Grant” means an Option granted annually to all Non-Employee Directors who meet
the specified criteria pursuant to Section 6(c).

1.

 

     (i) “Common Stock” means the common stock of the Company.

     (j) “Company” means MannKind Corporation, a Delaware corporation.

     (k) “Consultant” means any person, including an advisor, who (i) is engaged by the Company or
an Affiliate to render consulting or advisory service and is compensated for such service or (ii)
is serving as a member of the Board of Directors of an Affiliate and is compensated for such
service. However, service solely as a Director, or payment of a fee for such service, shall not
cause a Director to be considered a “Consultant” for purposes of the Plan.

     (l) “Continuous Service” means that the Optionholder’s service with the Company or an
Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. The
Optionholder’s Continuous Service shall not be deemed to have terminated merely because of a change
in the capacity in which the Optionholder renders service to the Company or an Affiliate as an
Employee, Consultant or Director or a change in the entity for which the Optionholder renders such
service, provided that there is no interruption or termination of the Optionholder’s Continuous
Service. For example, a change in status from a Non-Employee Director of the Company to a
Consultant of an Affiliate or an Employee of the Company will not constitute an interruption of
Continuous Service. The Board or the chief executive officer of the Company, in that party’s sole
discretion, may determine whether Continuous Service shall be considered interrupted in the case of
any leave of absence approved by that party, including sick leave, military leave or any other
personal leave. Notwithstanding the foregoing, a leave of absence shall be treated as Continuous
Service for purposes of vesting in an Option only to such extent as may be provided in the
Company’s leave of absence policy or in the written terms of the Optionholders’s leave of absence.

     (m) “Corporate Transaction” means the occurrence, in a single transaction or in a series of
related transactions, of any one or more of the following events:

          (i) a sale or other disposition of all or substantially all, as determined by the Board in its
discretion, of the consolidated assets of the Company and its Subsidiaries;

          (ii) a sale or other disposition of at least ninety percent (90%) of the outstanding
securities of the Company;

          (iii) a merger, consolidation or similar transaction following which the Company is not the
surviving corporation; or

          (iv) a merger, consolidation or similar transaction following which the Company is the
surviving corporation but the shares of Common Stock outstanding immediately preceding the merger,
consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash
or otherwise.

     (n) “Director” means a member of the Board of Directors of the Company.

2.

 

     (o) “Disability” means the inability of a person, in the opinion of a qualified physician
acceptable to the Company, to perform the major duties of that person’s position with the Company
or an Affiliate of the Company because of the sickness or injury of the person.

     (p) “Employee” means any person employed by the Company or an Affiliate. However, service
solely as a Director, or payment of a fee for such service, shall not cause a Director to be
considered an “Employee” for purposes of the Plan.

     (q) “Entity” means a corporation, partnership or other entity.

     (r) “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     (s) “Fair Market Value” means, as of any date, the value of the Common Stock determined as
follows:

          (i) If the Common Stock is listed on any established stock exchange or traded on the Nasdaq
National Market or the Nasdaq SmallCap Market, the Fair Market Value of a share of Common Stock
shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as
quoted on such exchange or market (or the exchange or market with the greatest volume of trading in
the Common Stock) on the last market trading day prior to the day of determination, as reported in
The Wall Street Journal or such other source as the Board deems reliable.

          (ii) In the absence of such markets for the Common Stock, the Fair Market Value shall be
determined in good faith by the Board.

     (t) “Initial Grant” means an Option granted to a Non-Employee Director who meets the specified
criteria pursuant to Section 6(a).

     (u) “IPO Date” means the closing date of the initial public offering of the Common Stock.

     (v) “Non-Employee Director” means a Director who is not an Employee.

     (w) “Nonstatutory Stock Option” means an Option not intended to qualify as an incentive stock
option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.

     (x) “Officer” means a person who is an officer of the Company within the meaning of Section 16
of the Exchange Act and the rules and regulations promulgated thereunder.

     (y) “Option” means a Nonstatutory Stock Option granted pursuant to the Plan.

     (z) “Option Agreement” means a written agreement between the Company and an Optionholder
evidencing the terms and conditions of an individual Option grant. Each Option Agreement shall be
subject to the terms and conditions of the Plan.

3.

 

     (aa) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Option.

     (bb) “Own,” “Owned,” “Owner,” “Ownership” A person or Entity shall be deemed to “Own,” to
have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or
Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or
otherwise, has or shares voting power, which includes the power to vote or to direct the voting,
with respect to such securities.

     (cc) “Plan” means this MannKind Corporation 2003 Non-Employee Directors’ Stock Option Plan.

     (dd) “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule
16b-3, as in effect from time to time.

     (ee) “Securities Act” means the Securities Act of 1933, as amended.

     (ff) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than
fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a
majority of the board of directors of such corporation (irrespective of whether, at the time, stock
of any other class or classes of such corporation shall have or might have voting power by reason
of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company,
and (ii) any partnership in which the Company has a direct or indirect interest (whether in the
form of voting or participation in profits or capital contribution) of more than fifty percent
(50%).

3. Administration.

     (a) Administration by Board. The Plan shall be administered by the Board unless and until the
Board delegates administration of the Plan to a Committee, as provided in Section 3(c).

     (b) Powers of Board. The Board shall have the power, subject to, and within the limitations
of, the express provisions of the Plan:

          (i) To determine the provisions of each Option to the extent not specified in the Plan.

          (ii) To construe and interpret the Plan and Options granted under it, and to establish, amend
and revoke rules and regulations for its administration. The Board, in the exercise of this power,
may correct any defect, omission or inconsistency in the Plan or in any Option Agreement, in a
manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.

          (iii) To effect, at any time and from time to time, with the consent of any adversely affected
Optionholder, (1) the reduction of the exercise price of any outstanding Option under the Plan, (2)
the cancellation of any outstanding Option under the Plan and the grant in substitution therefor of
(A) a new Option under the Plan or another equity plan of the

4.

 

Company covering the same or a different number of shares of Common Stock, (B) cash and/or (C)
other valuable consideration (as determined by the Board, in its sole discretion), or (3) any other
action that is treated as a repricing under generally accepted accounting principles.

          (iv) To amend the Plan or an Option as provided in Section 12.

          (v) To terminate or suspend the Plan as provided in Section 13.

          (vi) Generally, to exercise such powers and to perform such acts as the Board deems necessary
or expedient to promote the best interests of the Company and that are not in conflict with the
provisions of the Plan.

     (c) Delegation to Committee. The Board may delegate administration of the Plan to a Committee
or Committees of one or more members of the Board, and the term “Committee” shall apply to any
person or persons to whom such authority has been delegated. If administration is delegated to a
Committee, the Committee shall have, in connection with the administration of the Plan, the powers
theretofore possessed by the Board, including the power to delegate to a subcommittee any of the
administrative powers the Committee is authorized to exercise (and references in this Plan to the
Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions,
not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.
The Board may abolish the Committee at any time and revest in the Board the administration of the
Plan.

     (d) Effect of Board’s Decision. All determinations, interpretations and constructions made by
the Board in good faith shall not be subject to review by any person and shall be final, binding
and conclusive on all persons.

4. Shares Subject to the Plan.

     (a) Share Reserve. Subject to the provisions of Section 11(a) relating to Capitalization
Adjustments, the shares of Common Stock that may be issued pursuant to Options shall not exceed in
the aggregate eight hundred thousand (800,000) shares of Common Stock.

     (b) Reversion of Shares to the Share Reserve. If any Option shall for any reason expire or
otherwise terminate, in whole or in part, without having been exercised in full, the shares of
Common Stock not acquired under such Option shall revert to and again become available for issuance
under the Plan. If any shares subject to an Option are not delivered to an Optionholder because
such shares are withheld for the payment of taxes or the Option is exercised through a reduction of
shares subject to the Option (i.e., “net exercised”), the number of shares that are not delivered
to the Optionholder as a result thereof shall remain available for issuance under the Plan. If the
exercise price of an Option is satisfied by tendering shares of Common Stock held by the
Optionholder (either by actual delivery or attestation), then the number of shares so tendered
shall remain available for issuance under the Plan.

     (c) Source of Shares. The shares of Common Stock subject to the Plan may be unissued shares
or reacquired shares, bought on the market or otherwise.

5.

 

5. Eligibility.

     The Options, as set forth in Section 6, automatically shall be granted under the Plan to all
Non-Employee Directors who meet the criteria specified in Section 6.

6. Non-Discretionary Grants.

     (a) Initial Grants. Without any further action of the Board, each person who is serving as a
Non-Employee Director on the IPO Date automatically shall, on the IPO Date, be granted an Initial
Grant to purchase thirty thousand (30,000) shares of Common Stock on the terms and conditions set
forth herein. Additionally, without any further action of the Board, each person who after the IPO
Date is elected or appointed for the first time to be a Non-Employee Director automatically shall,
upon the date of his or her initial election or appointment to be a Non-Employee Director, be
granted an Initial Grant to purchase thirty thousand (30,000) shares of Common Stock on the terms
and conditions set forth herein.

     (b) Annual Grants. Without any further action of the Board, on the date of each Annual
Meeting, commencing with the Annual Meeting in 2005, each person who is then a Non-Employee
Director automatically shall be granted an Annual Grant to purchase ten thousand (10,000) shares of
Common Stock on the terms and conditions set forth herein; provided, however, that if the person
has not been serving as a Non-Employee Director for the entire period since the preceding Annual
Meeting, then the number of shares subject to such Annual Grant shall be reduced pro rata for each
full quarter prior to the date of grant during which such person did not serve as a Non-Employee
Director.

7. Option Provisions.

     Each Option shall be in such form and shall contain such terms and conditions as required by
the Plan. Each Option shall contain such additional terms and conditions, not inconsistent with
the Plan, as the Board shall deem appropriate. Each Option shall include (through incorporation of
provisions hereof by reference in the Option or otherwise) the substance of each of the following
provisions:

     (a) Term. No Option shall be exercisable after the expiration of ten (10) years from the date
on which it was granted.

     (b) Exercise Price. The exercise price of each Option shall be one hundred percent (100%) of
the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted.

     (c) Consideration. The purchase price of Common Stock acquired pursuant to an Option shall be
paid, to the extent permitted by applicable law, either (i) in cash at the time the Option is
exercised or (ii) at the discretion of the Board either at the time of the grant of the Option or
subsequent thereto (1) by delivery to the Company of other Common Stock at the time the Option is
exercised, (2) by a “net exercise” of the Option (as further described below), (3) pursuant to a
program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the
issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the
receipt of irrevocable instructions to pay the aggregate exercise price to

6.

 

the Company from the sales proceeds or (4) in any other form of legal consideration that may
be acceptable to the Board. Unless otherwise specifically provided in the Option, the purchase
price of Common Stock acquired pursuant to an Option that is paid by delivery to the Company of
other Common Stock acquired, directly or indirectly from the Company, shall be paid only by shares
of the Common Stock of the Company that have been held for more than six (6) months (or such longer
or shorter period of time required to avoid a charge to earnings for financial accounting
purposes).

     In the case of a “net exercise” of an Option, the Company will not require a payment of the
exercise price of the Option from the Participant but will reduce the number of shares of Common
Stock issued upon the exercise by the largest number of whole shares that has a Fair Market Value
that does not exceed the aggregate exercise price. With respect to any remaining balance of the
aggregate exercise price, The Company shall accept a cash payment from the Participant. Shares of
Common Stock will no longer be outstanding under an Option (and will therefore not thereafter be
exercisable) following the exercise of such Option to the extent of (i) shares used to pay the
exercise price of an Option under a “net exercise”, (ii) shares actually delivered to the
Participant as a result of such exercise and (iii) shares withheld for purposes of tax withholding.

     (d) Transferability. An Option is transferable by will or by the laws of descent and
distribution. An Option also may be transferable upon written consent of the Company if, at the
time of transfer, a Form S-8 registration statement under the Securities Act is available for the
exercise of the Option and the subsequent resale of the underlying securities. In addition, an
Optionholder may, by delivering written notice to the Company, in a form provided by or otherwise
satisfactory to the Company, designate a third party who, in the event of the death of the
Optionholder, shall thereafter be entitled to exercise the Option.

     (e) Vesting. Initial Grants shall vest in three (3) equal annual installments on each
anniversary of the IPO Date, in the case of each person who is serving as a Non-Employee Director
on the IPO Date, or on each anniversary of his or her initial election or appointment to be a
Non-Employee Director, in the case of each person who after the IPO Date is elected or appointment
for the first time to be a Non-Employee Director. Annual Grants shall vest in thirty-six (36)
equal monthly installments commencing one month from the date of grant.

     (f) Termination of Continuous Service. In the event an Optionholder’s Continuous Service
terminates for any reason, the Optionholder may exercise his or her Option (to the extent that the
Optionholder was entitled to exercise it as of the date of termination) but only within such period
of time ending on the expiration of the term of the Option as set forth in the Option Agreement.
If, after termination, the Optionholder does not exercise his or her Option within the time
specified in the Option Agreement, the Option shall terminate.

8. Securities Law Compliance.

     The Company shall seek to obtain from each regulatory commission or agency having jurisdiction
over the Plan such authority as may be required to grant Options and to issue and sell shares of
Common Stock upon exercise of the Options; provided, however, that this undertaking shall not
require the Company to register under the Securities Act the Plan, any Option or any

7.

 

Common Stock issued or issuable pursuant to any such Option. If, after reasonable efforts,
the Company is unable to obtain from any such regulatory commission or agency the authority which
counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the
Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock
upon exercise of such Options unless and until such authority is obtained.

9. Use of Proceeds from Stock.

     Proceeds from the sale of Common Stock pursuant to Options shall constitute general funds of
the Company.

10. Miscellaneous.

     (a) Stockholder Rights. No Optionholder shall be deemed to be the holder of, or to have any
of the rights of a holder with respect to, any shares of Common Stock subject to such Option unless
and until such Optionholder has satisfied all requirements for exercise of the Option pursuant to
its terms.

     (b) No Service Rights. Nothing in the Plan or any instrument executed or Option granted
pursuant thereto shall confer upon any Optionholder any right to continue to serve the Company as a
Non-Employee Director or shall affect the right of the Company or an Affiliate to terminate (i) the
employment of an Employee with or without notice and with or without cause, (ii) the service of a
Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate or
(iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any
applicable provisions of the corporate law of the state in which the Company or the Affiliate is
incorporated, as the case may be.

     (c) Investment Assurances. The Company may require an Optionholder, as a condition of
exercising or acquiring Common Stock under any Option, (i) to give written assurances satisfactory
to the Company as to the Optionholder’s knowledge and experience in financial and business matters
and/or to employ a purchaser representative reasonably satisfactory to the Company who is
knowledgeable and experienced in financial and business matters and that he or she is capable of
evaluating, alone or together with the purchaser representative, the merits and risks of exercising
the Option; and (ii) to give written assurances satisfactory to the Company stating that the
Optionholder is acquiring the Common Stock subject to the Option for the Optionholder’s own account
and not with any present intention of selling or otherwise distributing the Common Stock. The
foregoing requirements, and any assurances given pursuant to such requirements, shall be
inoperative if (1) the issuance of the shares of Common Stock upon the exercise or acquisition of
Common Stock under the Option has been registered under a then currently effective registration
statement under the Securities Act or (2) as to any particular requirement, a determination is made
by counsel for the Company that such requirement need not be met in the circumstances under the
then applicable securities laws. The Company may, upon advice of counsel to the Company, place
legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate
in order to comply with applicable securities laws, including, but not limited to, legends
restricting the transfer of the Common Stock.

8.

 

     (d) Withholding Obligations. To the extent provided by the terms of an Option Agreement, the
Company may in its sole discretion, satisfy any federal state or local tax withholding obligation
relating to an Option by any of the following means (in addition to the Company’s right to withhold
from any compensation paid to the Participant by the Company) or by a combination of such means:
(i) causing the Optionholder to tender a cash payment; (ii) withholding shares of Common Stock from
the shares of Common Stock issued or otherwise issuable to the Optionholder in connection with the
Option; or (iii) via such other method as may be set forth in the Option Agreement.

11. Adjustments upon Changes in Common Stock.

     (a) Capitalization Adjustments. If any change is made in, or other event occurs with respect
to, the Common Stock subject to the Plan, or subject to any Option, without the receipt of
consideration by the Company (through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating
dividend, combination of shares, exchange of shares, change in corporate structure or other
transaction not involving the receipt of consideration by the Company (each a “Capitalization
Adjustment”), the Plan will be appropriately adjusted in the class(es) and maximum number of
securities subject both to the Plan pursuant to Section 4 and to the nondiscretionary Options
specified in Section 6, and the outstanding Options will be appropriately adjusted in the class(es)
and number of securities and price per share of Common Stock subject to such outstanding Options.
The Board shall make such adjustments, and its determination shall be final, binding and
conclusive. (Notwithstanding the foregoing, the conversion of any convertible securities of the
Company shall not be treated as a transaction “without receipt of consideration” by the Company.)

     (b) Dissolution or Liquidation. In the event of a dissolution or liquidation of the Company,
then all outstanding Options shall terminate immediately prior to the completion of such
dissolution or liquidation.

     (c) Corporate Transaction. In the event of a Corporate Transaction, any surviving corporation
or acquiring corporation may assume or continue any or all Options outstanding under the Plan or
may substitute similar stock options for Options outstanding under the Plan (including, but not
limited to, options to acquire the same consideration paid to the stockholders of the Company, as
the case may be, pursuant to the Corporate Transaction). In the event that any surviving
corporation or acquiring corporation does not assume or continue all such outstanding Options or
substitute similar stock options for all such outstanding Options, then with respect to Options
that have been not assumed, continued or substituted, the Options shall terminate if not exercised
(if applicable) at or prior to the effective time of such Corporate Transaction.

12. Amendment of the Plan and Options.

     (a) Amendment of Plan. Subject to the limitations, if any, of applicable law, the Board, at
any time and from time to time, may amend the Plan. However, except as provided in Section 11(a)
relating to Capitalization Adjustments, no amendment shall be effective unless

9.

 

approved by the stockholders of the Company to the extent stockholder approval is necessary to
satisfy the requirements of applicable law.

     (b) Stockholder Approval. The Board, in its sole discretion, may submit any other amendment
to the Plan for stockholder approval.

     (c) No Impairment of Rights. Rights under any Option granted before amendment of the Plan
shall not be impaired by any amendment of the Plan unless (i) the Company requests the consent of
the Optionholder and (ii) the Optionholder consents in writing.

     (d) Amendment of Options. The Board, at any time, and from time to time, may amend the terms
of any one or more Options, including, but not limited to, amendments to provide terms more
favorable than previously provided in the agreement evidencing an Option, subject to any specified
limits in the Plan that are not subject to Board discretion; provided, however, that the rights
under any Option shall not be impaired by any such amendment unless (i) the Company requests the
consent of the Optionholder and (ii) the Optionholder consents in writing.

13. Termination or Suspension of the Plan.

     (a) Plan Term. The Board may suspend or terminate the Plan at any time. No Options may be
granted under the Plan while the Plan is suspended or after it is terminated.

     (b) No Impairment of Rights. Suspension or termination of the Plan shall not impair rights
and obligations under any Option granted while the Plan is in effect except with the written
consent of the Optionholder.

14. Effective Date of Plan.

     The Plan shall become effective on the IPO Date, but no Option shall be exercised unless and
until the Plan has been approved by the stockholders of the Company, which approval shall be within
twelve (12) months before or after the date the Plan is adopted by the Board.

15. Choice of Law.

     The law of the state of California shall govern all questions concerning the construction,
validity and interpretation of this Plan, without regard to such state’s conflict of laws rules.

10.

 

MannKind Corporation

2004 Non-Employee Directors’ Stock Option Plan

Stock Option Agreement

     Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option
Agreement, MannKind Corporation (the “Company”) has granted you an option under its 2004
Non-Employee Directors’ Stock Option Plan (the “Plan”) to purchase the number of shares of the
Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant
Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the
Plan shall have the same definitions as in the Plan.

     The details of your option are as follows:

     1. Vesting. Subject to the limitations contained herein, your option will vest as
provided in your Grant Notice, provided that vesting will cease upon the termination of your
Continuous Service.

     2. Number of Shares and Exercise Price. The number of shares of Common Stock subject
to your option and your exercise price per share referenced in your Grant Notice may be adjusted
from time to time for Capitalization Adjustments, as provided in the Plan.

     3. Method of Payment. Payment of the exercise price is due in full upon exercise of
all or any part of your option. You may elect to make payment of the exercise price in cash or by
check or in any other manner permitted by your Grant Notice, which may include one or more
of the following:

          (a) In the Company’s sole discretion at the time your option is exercised and provided that at
the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street
Journal, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve
Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check)
by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to
the Company from the sales proceeds.

          (b) Provided that at the time of exercise the Common Stock is publicly traded and quoted
regularly in The Wall Street Journal, by delivery of already-owned shares of Common Stock either
that you have held for the period required to avoid a charge to the Company’s reported earnings
(generally six months) or that you did not acquire, directly or indirectly from the Company, that
are owned free and clear of any liens, claims, encumbrances or security interests, and that are
valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole
discretion of the Company at the time you exercise your option, shall include delivery to the
Company of your attestation of ownership of such shares of Common Stock in a form approved by the
Company. Notwithstanding the foregoing, you may not exercise your option by tender to the Company
of Common Stock to the extent such tender would violate the provisions of any law, regulation or
agreement restricting the redemption of the Company’s stock.

 

 

     4. Whole Shares. You may exercise your option only for whole shares of Common Stock.

     5. Securities Law Compliance. Notwithstanding anything to the contrary contained
herein, you may not exercise your option unless the shares of Common Stock issuable upon such
exercise are then registered under the Securities Act or, if such shares of Common Stock are not
then so registered, the Company has determined that such exercise and issuance would be exempt from
the registration requirements of the Securities Act. The exercise of your option must also comply
with other applicable laws and regulations governing your option, and you may not exercise your
option if the Company determines that such exercise would not be in material compliance with such
laws and regulations.

     6. Term. You may not exercise your option before the commencement of its term or
after its term expires. The term of your option commences on the Date of Grant and expires upon
the earliest of the following:

          (a) three (3) months after the termination of your Continuous Service for any reason other
than your Disability or death, provided that if during any part of such three- (3-) month period
your option is not exercisable solely because of the condition set forth in the preceding paragraph
relating to “Securities Law Compliance,” your option shall not expire until the earlier of the
Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months
after the termination of your Continuous Service;

          (b) twelve (12) months after the termination of your Continuous Service due to your
Disability;

          (c) eighteen (18) months after your death if you die either during your Continuous Service or
within three (3) months after your Continuous Service terminates;

          (d) the Expiration Date indicated in your Grant Notice; or

          (e) the day before the tenth (10th) anniversary of the Date of Grant.

7. Exercise.

          (a) You may exercise your option during its term by delivering a Notice of Exercise (in a form
designated by the Company) together with the exercise price to the Secretary of the Company, or to
such other person as the Company may designate, during regular business hours, together with such
additional documents as the Company may then require.

          (b) By exercising your option you agree that, as a condition to any exercise of your option,
the Company may require you to enter into an arrangement providing for the payment by you to the
Company of any tax withholding obligation of the Company arising by reason of (1) the exercise of
your option, (2) the lapse of any substantial risk of forfeiture to which the shares of Common
Stock are subject at the time of exercise, or (3) the disposition of shares of Common Stock
acquired upon such exercise.

2.

 

     8. Transferability. Your option is not transferable, except by will or by the laws
of descent and distribution, and is exercisable during your life only by you. Notwithstanding the
foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you
may designate a third party who, in the event of your death, shall thereafter be entitled to
exercise your option.

     9. Option not a Service Contract. Your option is not an employment or service
contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation
on your part to continue in the employ of the Company or an Affiliate, or of the Company or an
Affiliate to continue your employment. In addition, nothing in your option shall obligate the
Company or an Affiliate, their respective shareholders, Boards of Directors, Officers or Employees
to continue any relationship that you might have as a Director or Consultant for the Company or an
Affiliate.

     10. Withholding Obligations.

          (a) At the time you exercise your option, in whole or in part, or at any time thereafter as
requested by the Company, you hereby authorize withholding from payroll and any other amounts
payable to you, and otherwise agree to make adequate provision for (including by means of a
“cashless exercise” pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the
federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if
any, which arise in connection with your option.

          (b) Upon your request and subject to approval by the Company, in its sole discretion, and
compliance with any applicable conditions or restrictions of law, the Company may withhold from
shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole
shares of Common Stock having a Fair Market Value, determined by the Company as of the date of
exercise, not in excess of the minimum amount of tax required to be withheld by law. If the date
of determination of any tax withholding obligation is deferred to a date later than the date of
exercise of your option, share withholding pursuant to the preceding sentence shall not be
permitted unless you make a proper and timely election under Section 83(b) of the Code, covering
the aggregate number of shares of Common Stock acquired upon such exercise with respect to which
such determination is otherwise deferred, to accelerate the determination of such tax withholding
obligation to the date of exercise of your option. Notwithstanding the filing of such election,
shares of Common Stock shall be withheld solely from shares of Common Stock determined as of the
date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse
consequences to you arising in connection with such share withholding procedure shall be your sole
responsibility.

          (c) You may not exercise your option unless the tax withholding obligations of the Company
and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when
desired, and the Company shall have no obligation to issue a certificate for such shares of Common
Stock or release such shares of Common Stock from any escrow provided for herein.

3.

 

     11. Notices. Any notices provided for in your option or the Plan shall be given in
writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by
mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid,
addressed to you at the last address you provided to the Company.

     12. Governing Plan Document. Your option is subject to all the provisions of the
Plan, the provisions of which are hereby made a part of your option, and is further subject to all
interpretations, amendments, rules and regulations which may from time to time be promulgated and
adopted pursuant to the Plan. In the event of any conflict between the provisions of your option
and those of the Plan, the provisions of the Plan shall control.

4.exv10w23

 

Exhibit 10.23

NOTE: Portions of this Exhibit are the subject of a Confidential Treatment
Request by the Registrant to the Securities and Exchange Commission. Such
portions have been redacted and are marked with a “[*]” in place of the redacted
language.

RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT

     This Research and Commercial License Option Agreement (the “Agreement”) is made
and entered into as of October 1, 2005 (the “Effective Date”) by and between Sangamo
BioSciences, Inc., a Delaware corporation having its principal place of business at Point
Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and
Dow AgroSciences LLC, a Delaware limited liability company having its principal place of
business at 9330 Zionsville Road, Indianapolis, Indiana 46268 (“DAS”). Sangamo and DAS are
sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Recitals

     A. Sangamo has expertise in, and proprietary technology relating to, zinc finger proteins and
their use to alter the genomes and/or protein expression capabilities of organisms and cells,
including plants and plant cells.

     B. DAS has expertise in the use of genetically modified and traditionally bred plants and
plant cell cultures for agricultural and industrial purposes as well as for the production of
vaccines and therapeutic products for human and/or animal health.

     C. DAS desires an exclusive license option under Sangamo’s expertise and proprietary
technology as applied to plant cells, plants, and plant cell cultures, and Sangamo desires to grant
such an option, and both DAS and Sangamo desire to establish a research collaboration to validate
and optimize the application of such Sangamo expertise and technology to plants, plant cells and
plant cell cultures for agricultural, industrial, and vaccine and therapeutic product production
purposes.

     Now, Therefore, the Parties agree as follows:

 1.

 

ARTICLE 1

DEFINITIONS

     1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership,
or other entity that controls, is controlled by or is under common control with such Party. For
the purposes of the definition in this Section 1.1, the word “control” (including, with correlative
meaning, the terms “controlled by” or “under the common control with”) means the actual power,
either directly or indirectly through one or more intermediaries, to direct the management and
policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting
stock of such entity, or by contract or otherwise.

     1.2 “Animal Health Product” a Licensed Product that is used for diagnosis, treatment or
prophylaxis of a disease or medical condition in a non-human animal, for reducing or eliminating
pathogens in a non-human animal, or for nutritional supplements or food additives for nutritional
enhancements in a non-human animal.

     1.3 “Annual FTE Rate” means (a) for each year of the Initial Research Term (i.e., until the
third anniversary of the Effective Date), $*** per FTE and (b) for each year of the
Subsequent Research Term, $*** per FTE plus an additional four percent (4%), compounded
annually, as a cost of living adjustment.

     1.4 “Average Net Unit Return of the Trait” or “ANURT” shall be calculated using the following
formula:

     ANURT = ***

     wherein

     R is the DAS reference price, which reference price shall in each case be equal to the Net
Unit Return for a unit of the germplasm into which the applicable ZFP Trait was inserted or
created. In the event the pure germplasm is not sold in sufficient volume to establish a reference

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

 2.

 

price, then the Net Unit Return for the nearest competitive germplasm will be used as the
reference price, and if substantially all of the competitive germplasm is marketed with a
particular Other Trait (referred to hereinafter as an “embedded” Trait – an example is glyphosate
tolerance in soybeans), the reference price will be for germplasm with the embedded Trait.

     ANURP is the Net Unit Return price for a unit of the germplasm of the resulting Crop Product
containing such ZFP Trait;

     N is the number of separate and commercially distinguishable Traits (both ZFP Traits and Other
Traits) in such Crop Product (excluding any embedded Trait present in the reference germplasm); and

     TPTR is the royalties, if any, paid by DAS to a Third Party with respect to the ZFP Trait in
such Crop Product.

     1.5 “CEO” shall have the meaning assigned to it in Section 3.5(d).

     1.6 “Collaboration” means all activities performed by or on behalf of Sangamo or DAS in the
course of performing the activities described in, or fulfilling of their obligations pursuant to,
this Agreement.

     1.7 “Confidential Information” shall have the meaning assigned to it in Section 10.1.

     1.8 “Contract Manufacturer” means a Third Party contractor capable of carrying out the
Manufacture of ZFP Products at a quantity level and volume sufficient to supply Sangamo and DAS for
their activities under this Agreement and Sublicensees in accordance with the terms of their
Technology Licenses or their research licenses granted by DAS pursuant to Section 2.1(a)(ii).

     1.9 “Control” means, with respect to an item of Information or intellectual property right,
that a Party owns or has a license to such item or right and has the ability to disclose such item
and/or grant a license or sublicense as provided for in this Agreement under such item or right
without violating the terms of any agreement or other arrangement with any Third Party.

 3.

 

     1.10 “Core Patents” means (a) the United States Sangamo Patents listed in Exhibit B; (b) any
non-provisional applications, additions, continuations, continuations-in-part, divisions and
substitutes thereof; and (c) any reissue, re-examination, extension or patent term extension of any
such patent.

     1.11 “Crop Product” means a Licensed Product that is a human or animal food, human or animal
food ingredient, or is used to produce a human food, human food ingredient, or is a fiber.
Notwithstanding the foregoing, Crop Product shall not include any Animal Health Product, Human
Health Product or Industrial Product.

     1.12 “DAS Improvements” means (a) Improvements (other than Joint Improvements) that are made
by one or more employees, consultants, or independent contractors of DAS or any DAS Affiliate; and
(b) Improvements made by Sublicensees pursuant to research licenses granted by DAS pursuant to
Section 2.1(a)(ii), to the extent owned or controlled by DAS or any DAS Affiliate.

     1.13 “DAS Improvement Patent” means any Improvement Patent that claims a DAS Improvement.

     1.14 “DAS Product” means any Licensed Product arising from DAS’s or its Affiliate’s activities
in the Field (a Licensed Product arising solely from a Sublicensee’s activities in the Field is not
included in DAS Product).

     1.15 “DAS Program Inventions” means (a) Program Inventions (other than Joint Program
Inventions) that are made by one or more employees, consultants, or independent contractors of DAS
or any DAS Affiliate, and (b) Program Inventions made by Sublicensees, to the extent owned or
controlled by DAS or any DAS Affiliate.

     1.16 “DAS Program Patent” means a Program Patent that claims a DAS Program Invention.

     1.17 “DAS ZFP Trait” means a ZFP Trait arising from DAS’s activities in the Field.

     1.18 “Diligent Efforts” means the carrying out of obligations or tasks in a sustained manner
consistent with the efforts a Party devotes to a product or a research, development or

 4.

 

marketing project of similar market potential, profit potential or strategic value resulting
from its own research efforts, based on conditions then prevailing. Diligent Efforts requires that
the Party: (a) promptly assign responsibility for such obligations to specific employee(s) who are
held accountable for progress and monitor such progress on an on-going basis, (b) set and
consistently seek to achieve specific and meaningful objectives for carrying out such obligations,
and (c) consistently make and implement decisions and allocate resources designed to advance
progress with respect to such objectives.

     1.19 “Field” means gene targeting and/or gene regulation using a ZFP Product to modify the
genome of a plant cell, plant, or plant cell culture (in each case, whether constituting or derived
from a vascular or non-vascular plant), or alter the nucleic acid or protein expression in a plant
cell, plant, or plant cell culture. For the purpose of this Agreement, “non-vascular” plants shall
include but not be limited to algae, moss, and fungi. Explicitly excluded from the Field are
delivery of any ZFP Product into a human or animal for diagnostic, therapeutic or prophylactic
purposes, and products intended to result in such delivery.

     1.20 “Field Specific Sangamo Patent” means any Sangamo Patent in which all claims are directed
to methods that are solely useful in the Field, or to compositions of matter or methods of
manufacture of ZFP Products that are solely useful in the Field. Exhibit A may be amended from
time to time to identify and update identification of Field Specific Sangamo Patents.

     1.21 “Food Safety Product” means an Animal Health Product for reducing or eliminating
pathogens in non-human animals that may be used to produce human food.

     1.22 “FTE” means the equivalent of one employee or consultant of Sangamo working full time for
one twelve (12) month period.

     1.23 “Full-scale Product Launch” means commercial offering of a product for an entire national
market or for an entire targeted market geography, as opposed to test marketing.

     1.24 “Generally Applicable Sangamo Patents” means all Sangamo Patents (other than Field
Specific Sangamo Patents) that claim compositions of matter or methods that are reasonably
necessary or useful in the Field. Exhibit A may be amended from time to time to

 5.

 

identify and update identification of Generally Applicable Sangamo Patents.

     1.25 “GMO Product” means any Crop Product that is a DAS Product and is not a Non-GMO Product.

     1.26 “Human Health Product” means any Licensed Product (a) that is intended for the diagnosis,
treatment or prophylaxis of a disease or medical condition in a human or (b) that is extracted from
plant material and intended to be ingested by or topically applied or otherwise delivered or
administered to humans, food, and food ingredients (e.g. oils), including without limitation
nutraceuticals, vitamins, nutritional supplements, food additives, shampoo, soap, sunscreen, and
cosmetics.

     1.27 “Improvement” means any enhancement, modification, or improvement to the Sangamo
Technology, whether patentable or not, made during the term of the Agreement by one or more
employees, consultants, or independent contractors of DAS, a DAS Affiliate, or a Sublicensee, but
excluding any Product Specific Invention. A “Joint Improvement” is an Improvement made by one or
more employees, consultants, or independent contractors of both Parties.

     1.28 “Improvement Patent” means any patent or patent application in the United States or any
foreign jurisdiction claiming an Improvement.

     1.29 “Industrial Product” means a Licensed Product that is (a) a raw material for
construction, textiles, or industrial applications (e.g. biomaterials, biofeedstocks, alternative
raw materials), (b) a plant or plant part that produces or is used as a product described in (a),
or (c) germplasm, seeds or other plant-derived material capable of propagating a plant described in
(b). Notwithstanding the foregoing, Industrial Product shall not include any Animal Health Product
or Human Health Product.

     1.30 “Information” means information, results and data of any type whatsoever, in any tangible
or intangible form whatsoever, including without limitation, databases, inventions, practices,
methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill,
experience, test data including pharmacological, biological, chemical, biochemical, toxicological
and clinical test data, analytical and quality control data, stability data, studies and

 6.

 

procedures, and patent and other legal information or descriptions.

     1.31 “Infringement” shall have the meaning set forth in Section 9.6(a).

     1.32 “Initial Research Term” means the period of time commencing on the Effective Date and
continuing, unless the Agreement is earlier terminated pursuant to Article 11, until the third
anniversary of the Effective Date.

     1.33 “Joint Inventions” means inventions, whether patentable or not, that are made by one or
more employees, consultants, or independent contractors of both Parties. Joint Program Inventions
are Joint Inventions that are Program Inventions. For clarity, Joint Inventions shall include
Joint Improvements, but shall exclude jointly made Product Specific Inventions.

     1.34 “Joint Patent” means a patent or patent application that claims a Joint Invention.
“Joint Program Patent” means a Joint Patent that claims a Joint Program Invention. “Joint
Improvement Patent” means a Joint Patent that claims a Joint Improvement.

     1.35 “Joint Research Team” or “JRT” means the committee described in Sections 3.4 and 3.6.

     1.36 “Joint Steering Committee” or “JSC” means the committee described in Sections 3.4 and
3.5.

     1.37 “Licensed Product” means any product, other than a ZFP Product, that is created or
produced directly or indirectly through use of Sangamo Technology in the Field by DAS or its
Affiliates or its Sublicensees. For clarity it is reiterated that the Field explicitly excludes
products intended to deliver into a human or an animal any ZFP Product for diagnostic, therapeutic
or prophylactic purposes; therefore Licensed Product also excludes such products.

     1.38 “Licensing Program” means the program under which DAS grants Technology Licenses to
Sublicensees, as described in more detail in Article 5.

     1.39 “Major Crop” means one of the following six crops: corn, cotton, canola oil/oil seed
rape, rice, wheat, and soybean.

 7.

 

     1.40 “Manufacture” or “Manufacturing” means the design, optimization, construction,
production, and testing of ZFP Product.

     1.41 “Minimum Annual Payment” means each payment described in Section 8.7.

     1.42 “Net Average Trait Value” means the Average Net Unit Return of the Trait multiplied by
the net volume sold of the applicable DAS Product.

     1.43 “Net Sales” means the amount invoiced or otherwise billed by DAS or its Affiliate or
sublicensee for sales or other commercial disposition of a DAS Product to a Third Party purchaser,
less the following to the extent included in such billing or otherwise actually allowed or incurred
with respect to such sales: (i) discounts, including cash, trade and quantity discounts, price
reduction programs, retroactive price adjustments with respect to sales of a product, charge-back
payments and rebates granted to trade customers; (ii) credits or allowances actually granted upon
rejections or returns of DAS Products, including for replants, recalls or damaged goods; (iii)
freight, postage, shipping and insurance charges actually allowed or paid for delivery of DAS
Products, to the extent billed; (iv) customs duties, surcharges and other governmental charges
incurred in connection with the exportation or importation of a DAS Product; (v) bad debts relating
to sales of DAS Products that are actually written off by the seller in accordance with generally
accepted accounting principles, consistently applied, during the applicable royalty calculation
period; and (vi) taxes, duties or other governmental charges levied on, absorbed or otherwise
imposed on sale of DAS Products, including without limitation value-added taxes, or other
governmental charges otherwise measured by the billing amount, when included in billing, as
adjusted for rebates and refunds, but specifically excluding taxes based on net income of the
seller; provided that all of the foregoing deductions are calculated in accordance with generally
accepted accounting principles consistently applied throughout the selling party’s organization.

Notwithstanding the foregoing, if any DAS Product is sold under a bundled or capitated arrangement
with other products, then, solely for the purpose of calculating Net Sales for royalty purposes
hereunder, any discount on such DAS Products sold under such an arrangement shall be no greater, on
a percentage basis based on the gross selling price prior to discount, than the largest percentage
discount applied on any other product sold within such bundled arrangement

 8.

 

for the applicable accounting period. In case of any dispute as to the applicable discount numbers
under the preceding sentence, the determination of same shall be calculated and certified by the
selling party’s independent public accountants, whose decision shall be binding.

For sake of clarity and avoidance of doubt, sales by DAS, its Affiliates or sublicensees of a DAS
Product to a Third Party distributor of such DAS Product in a given country shall be considered a
sale to a Third Party customer.

     1.44 “Net Unit Return” means Net Sales divided by the net number of units sold.

     1.45 “Non-GMO Designation” means that consultation with relevant regulatory authorities in the
United States, European Union, Japan, and Canada has confirmed that Regulatory Approval for a
particular Crop Product is not required in any of them.

     1.46 “Non-GMO Product” means a Crop Product that is a DAS Product and for which the criteria
of Non-GMO Designation have been satisfied.

     1.47 “Option Exercise Notice” means DAS’s notice pursuant to Section 2.2.

     1.48 “Option Period” means the period commencing on the Effective Date of this Agreement and
ending on Sangamo’s timely receipt of the Option Exercise Notice and the option fee set forth in
Section 8.6.

     1.49 “Other Trait” means a Trait that is introduced, enhanced, modified, deleted or otherwise
altered through methods that do not involve the use of ZFP Products.

     1.50 “Product Specific Invention” means an invention, whether patentable or not, that (a) is
made by (i) Sangamo in carrying out the Research Program or Manufacturing ZFP Products for DAS or
Sublicensees pursuant to Section 7.1 or (ii) DAS or its Affiliates or Sublicensees under this
Agreement and (b) is specific to (i) a ZFP Product that is directed to a particular DNA sequence in
a plant and solely useful for modifying the sequence or expression of a gene in such plant related
to such DNA sequence, or (ii) the modified form of such DNA sequence (or the modified protein
encoded by such modified DNA sequence) as found in the resulting Licensed Product.

 9.

 

     1.51 “Program Inventions” means inventions, other than Improvements and Product Specific
Inventions, that are (a) made by the Parties (or any Affiliates or Third Parties conducting
Research Program activities on behalf of a Party) in carrying out the Research Program, (b)
otherwise arising from DAS’s activities in the Field during the Option Period, or (c) made by
Sublicensees during the Option Period pursuant to research licenses granted by DAS pursuant to
Section 2.1(a)(ii).

     1.52 “Program Patent” means any patent or patent application in the United States or any
foreign jurisdiction that claims a Program Invention.

     1.53 “Regulatory Approval” means any and all approvals (including supplements, amendments,
pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations or
authorizations of any national, supra-national (e.g., the European Commission or the Council of the
European Union), regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity, that are necessary for the manufacture, distribution, use or
sale of a DAS Product in a regulatory jurisdiction, as well as applicable import approvals in Japan
and Canada. Regulatory Approval does not include a confirmation by a regulatory agency that its
approval is not required.

     1.54 “Research Budget” means the written budget prepared by Sangamo and presented to the JSC
for approval outlining a good faith approximation of FTE expenditures and all other costs and
expenses that Sangamo expects to incur in carrying out the tasks assigned to it under the Research
Plan.

     1.55 “Research Plan” means the written description of the overall program for the conduct of
the Research Program, including an allocation of responsibilities between the Parties for
implementation, as amended or revised from time to time by the JSC pursuant to Section 4.2. A
preliminary Research Plan for the Initial Research Term has been agreed upon by the Parties in a
separate side letter. The Research Plan shall include the Research Budget.

     1.56 “Research Program” means the collaborative research program undertaken by the Parties to
validate and optimize the application of the Sangamo Technology to the Field.

     1.57 “Research Term” means the Initial Research Term plus the Subsequent Research

 10.

 

Term.

     1.58 “Sangamo Know-How” means all Information (other than Sangamo Patents) that (a) is
Controlled, during the term of this Agreement, by Sangamo or by any entity that is a Sangamo
Affiliate during the Research Term and (b) is reasonably necessary or useful in the Field;
including any Sangamo Program Invention. Sangamo Know-How shall not include any Information
licensed to Sangamo or a Sangamo Affiliate by a Third Party unless such Information is licensed
pursuant to a Third Party License and meets the aforementioned criteria for Sangamo Know-How.

     1.59 “Sangamo Patent” means (a) any patent or patent application Controlled, during the term
of this Agreement, by Sangamo or by any entity that is a Sangamo Affiliate during the Research
Term, in the United States or any foreign jurisdiction, that is reasonably necessary or useful in
the Field or otherwise claims the composition of matter, manufacture, or use of ZFP Products; (b)
any non-provisional application, addition, continuation, continuation-in-part or division thereof
or any substitute application therefor; (c) any patents issuing on any of the foregoing; (d) any
reissue, re-examination, extension or patent term extension of any such patent, and any
confirmation patent or registration patent or patent of addition based on any such patent; and (e)
any foreign equivalent of the foregoing; including any Sangamo Program Patent. A patent or patent
application licensed to Sangamo or a Sangamo Affiliate by a Third Party shall not be a Sangamo
Patent unless such patent or patent application is licensed pursuant to a Third Party License and
meets the aforementioned criteria for a Sangamo Patent. Sangamo Patents identified as of the
Effective Date are listed in Exhibit A, which may be updated by Sangamo from time to time. Sangamo
Patents do not include DAS Improvement Patents, DAS Program Patents, or any patents on Improvements
made by Sublicensees. In Exhibit A, each Sangamo Patent may be designated as a Field Specific
Sangamo Patent or Generally Applicable Sangamo Patent as mutually agreed upon by the Parties.

     1.60 “Sangamo Program Inventions” means Program Inventions (other than Joint Program
Inventions) that are made by one or more employees, consultants, or independent contractors of
Sangamo or its Affiliates.

     1.61 “Sangamo Program Patent” means any Program Patent that claims a Sangamo

 11.

 

Program Invention.

     1.62 “Sangamo Technology” means the Sangamo Patents and the Sangamo Know-How.

     1.63 “Stacking Crop Product” means a Crop Product that (a) is a DAS Product, (b) is the direct
or indirect result of using one or more ZFP Products to produce a plant or plant cell comprising
Traits, where these Traits were each available in separate plants or plant cells that could have
been crossed to produce a breeding stack of the two Traits, and (c) is not the result of any other
activity in the Field.

     1.64 “Sublicensee” means a Third Party that has entered into a Technology License or received
a research license granted by DAS pursuant to Section 2.1(a)(ii).

     1.65 “Sublicensing Revenues” means any cash consideration that DAS receives from a Sublicensee
in connection with a Technology License, which may include (without limitation) upfront license
fees, annual license or maintenance payments, milestone payments, royalties, credits against DAS’
future expenses, or reductions in royalties or other payments otherwise owed to the Sublicensee.
Sublicensing Revenue also includes all cash consideration received by DAS in connection with any
research license it grants pursuant to Section 2.1(a)(ii). Sublicensing Revenue does not include
the value of non-cash consideration received by DAS, the Parties having expressly agreed that DAS
is not obligated to account to Sangamo for such consideration.

     1.66 “Subsequent Research Term” means the period of time commencing on the expiration of the
Initial Research Term and continuing until it is terminated in accordance with Section 4.1 or the
Agreement is terminated pursuant to Article 11, whichever is first.

     1.67 “Technology License” means an executed and in-force written agreement between DAS and a
Third Party, wherein such Third Party obtains a license under the Sangamo Technology to use ZFP
Products in the Field for the sole purpose of generating Licensed Products and to use, make, have
made, import, sell, and offer for sale such Licensed Products. Technology License does not include
a Trait license granted by DAS to a Third Party to commercialize a DAS Trait pursuant to Section
6.2, and does not include research licenses

 12.

 

granted by DAS pursuant to Section 2.1(a)(ii).

     1.68 “Third Party” means any entity other than (i) Sangamo, (ii) DAS or (iii) an Affiliate of
either Party.

     1.69 “Third Party License” shall mean (a) any of the agreements set forth in Exhibit C and (b)
any agreement that is deemed to be a Third Party License in accordance with the terms of Section
2.6(b).

     1.70 “Trait” means a distinguishing characteristic or quality of an organism resulting from
(a) modified expression of existing genes in the organism, (b) modification of the coding sequence
of an existing gene in the organism, or (c) insertion of DNA sequences from a different source.

     1.71 “Trait Crop Product” means a Crop Product that is a DAS Product but is not a Stacking
Trait Product.

     1.72 “ZFP Product” means a zinc-finger protein (including a zinc-finger transcription factor
or a zinc-finger nuclease), or a nucleic acid encoding and capable of expressing such protein in a
cell or tissue.

     1.73 “ZFP Trait” means a Trait that is introduced, enhanced, modified, deleted or otherwise
altered through activities in the Field.

ARTICLE 2

LICENSES

     2.1 Licenses to DAS

          (a) Grants to DAS Effective upon Signing. Subject to the terms and conditions of this
Agreement, Sangamo hereby grants to DAS and its Affiliates the following licenses and rights under
Sangamo Technology:

 13.

 

               (i) a world-wide, co-exclusive (with Sangamo) research license under Sangamo Technology to use
ZFP Products in the Field for research purposes and to make and test Licensed Products for research
purposes;

               (ii) the exclusive right to grant research licenses to Third Parties to use ZFP Products in
the Field for research purposes and to make and test Licensed Products for research purposes; and

               (iii) the exclusive right to grant to Sublicensees a license (A) to use ZFP Products in the
Field for the sole purpose of generating Licensed Products and (B) to use, make, offer to sell,
sell, and import such Licensed Products, all pursuant to Technology Licenses.

          (b) Additional Grants to DAS Effective after Exercise of Option. Subject to the terms and
conditions of this Agreement, Sangamo hereby grants to DAS and its Affiliates, effective upon DAS’s
exercise of the Option (which exercise shall include timely provision of the Option Exercise Notice
and timely payment of the fee set forth in Section 8.6), the following additional licenses and
rights under Sangamo Technology:

               (i) a royalty bearing, world-wide, exclusive license to make, use, and import ZFP Products for
use in the Field, which DAS shall exercise for the sole purposes of

                    (1) generating DAS Products; or

                    (2) offering for sale and selling ZFP Products at cost to Sublicensees for use in the Field
for the sole purpose of generating Licensed Products;

provided, however, that with respect to the Manufacture of ZFP Products for use in the Field, such
license is co-exclusive with Sangamo and any Contract Manufacturer, DAS shall not exercise such
license until Sangamo has transferred its Manufacturing technology to DAS pursuant to Section 7.2,
and Sangamo shall only use its coexclusive rights in the Field with respect to Manufacture of ZFP
Products to fulfill its obligations under Section 7.1; and

               (ii) a royalty bearing, world-wide, exclusive license to make, use, sell, offer for sale, and
import DAS Products.

 14.

 

          (c) Sublicensing. DAS shall not have the right to sublicense its right to grant research
licenses and Technology Licenses under Section 2.1(a) nor sublicense its rights under Section
2.1(b)(i), other than to a Contract Manufacturer selected by DAS and approved by Sangamo for the
sole purpose of Manufacturing ZFP products in accordance with the terms of this Agreement. The
license set forth in Section 2.1(b)(ii) shall be freely sublicensable. Sublicensees may be given
the right to further sublicense Licensed Products that they develop under Technology Licenses, and
Sublicensees may be given the right to license Third Parties to make, use, offer to sell, sell, or
import products containing ZFP Traits that the Sublicensees develop under Technology Licenses
(i.e., license their Traits), provided that licenses do not grant any sublicenses under or rights
with respect to Sangamo Technology.

          (d) Non-exclusive rights for Animal Health Products and Human Health Products.
Notwithstanding anything to the contrary in this Agreement, each of the licenses and rights granted
in 2.1(a) and 2.1(b) shall be non-exclusive with respect to Animal Health Products and Human Health
Products.

     2.2 Option Period. The Parties acknowledge and agree that the Research Program is intended to
provide DAS with an opportunity to evaluate the Sangamo Technology and the utility of ZFP Products
in the Field for the generation of Licensed Products and to determine whether DAS intends to
exercise the Option. Accordingly, unless DAS notifies Sangamo in writing on or before the third
anniversary of the Effective Date, that DAS desires to generate, develop and commercialize DAS
Products (such notice, the “Option Exercise Notice”) and timely pays the fee set forth in Section
8.6, this Agreement (including without limitation the licenses set forth in Section 2.1) shall
terminate in accordance with Section 11.3. DAS hereby covenants that DAS and its Affiliates will
not practice the licenses set forth in Section 2.1(b) during the Option Period.

     2.3 Licenses to Sangamo.

          (a) Manufacturing License. Subject to the terms and conditions of this Agreement, DAS hereby
grants to Sangamo and its Affiliates a worldwide, fully paid, license under the Improvements, DAS
Program Inventions, and Joint Program Inventions (and any patents or patent applications claiming
the same) solely to Manufacture ZFP Products for use in

 15.

 

the Field by DAS or its Sublicensees. Such license shall be sublicensable solely to a
Contract Manufacturer.

          (b) Licenses under Improvements and Program Inventions. Subject to the terms and conditions
of this Agreement, DAS hereby grants to Sangamo and its Affiliates a worldwide, fully paid,
perpetual, irrevocable (except pursuant to Section 11.2(e)), exclusive license (with the right to
sublicense) to practice the DAS Improvements, Joint Improvements, DAS Program Inventions, and Joint
Program Inventions (and all patents and patent applications claiming the same) for all purposes
outside the Field.

     2.4 Sangamo Retained Rights.

          (a) Notwithstanding anything to the contrary in this Agreement, Sangamo shall retain the
exclusive right to make and use ZFP Products for uses outside the Field.

          (b) Sangamo retains the right to use Sangamo Technology in yeast and to grant Third Parties
the right to use Sangamo Technology in yeast. (It is intended that DAS has a non-exclusive right
to use Sangamo Technology in yeast in accordance with Section 2.1.)

     2.5 Negative Covenants.

          (a) DAS hereby covenants that it shall not use or practice, nor shall it cause or permit any
of its Affiliates or sublicensees (including Sublicensees) to use or practice, directly or
indirectly, any Sangamo Technology for any other purposes other than those expressly permitted by
this Agreement.

          (b) Sangamo hereby covenants that it shall not use or practice, nor shall it cause or permit
any of its any Affiliates or sublicensees to, use or practice, directly or indirectly, any DAS
Improvement, DAS Program Invention, or Product Specific Invention for any other purposes other than
those expressly permitted by this Agreement.

     2.6 Third Party Licenses.

          (a) The licenses granted to DAS in Section 2.1 include sublicenses under Sangamo Technology
licensed to Sangamo pursuant to Third Party Licenses. Such sublicenses

 16.

 

are subject to (i) the limitations set forth in the Third Party Licenses (including without
limitation any limitations on the scope and exclusivity of the licenses granted to Sangamo
thereunder and any constraints on Sangamo’s ability to prosecute or enforce Sangamo Patents
licensed pursuant to such Third Party Licenses) and (ii) DAS’s satisfaction of the non-financial
terms and conditions of the Third Party Licenses, including without limitation those terms set
forth on Exhibit D. DAS understands and acknowledges that (1) the Collaborative Agreement between
Gendaq Limited and *** dated *** (the “*** Agreement”)is not a
Third Party License, (2) the licenses granted to DAS under Section 2.1 do not include sublicenses
of any licenses received by Sangamo under the ***Agreement as a result of Sangamo’s
acquisition of Gendaq Limited, and (3) with respect to any patents or patent applications included
within the Sangamo Patents that are addressed in the *** Agreement, the licenses granted
to DAS in Section 2.1 to such patents and patent applications are only licenses under Sangamo’s
ownership interest in such patents and patent applications. DAS further understands and
acknowledges that, notwithstanding the fact that the Patent License Agreement between
*** and Sangamo dated ***, as amended, (the “*** Agreement”) is a
Third Party License, (A) the licenses granted to DAS under Section 2.1 do not include sublicenses
under the patents and patent applications licensed to Sangamo pursuant to the Fifth Amendment to
the ***Agreement (such amendment being dated ***) and (B) such patents and
patent applications are not Sangamo Patents.

          (b) The licenses granted to DAS in Section 2.1 shall only be expanded to include sublicenses
under intellectual property licensed to Sangamo by a Third Party after the Effective Date (and the
license agreement under which such intellectual property is licensed to Sangamo shall only be
deemed to be a Third Party License) if:

               (i) such intellectual property is reasonably necessary or useful in the Field and Sangamo’s
license thereto includes the Field;

               (ii) Sangamo discloses the substantive terms of such agreement to DAS for review a reasonable
amount of time in advance of Sangamo’s anticipated entry into such a license agreement (which
Sangamo hereby covenants to do); and

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

 17.

 

               (iii) DAS provides Sangamo with written notice, prior to Sangamo’s entry into such license
agreement, in which (1) DAS consents to adding such license agreement to the definition of Third
Party License, (2) DAS assumes the obligations set forth in Section 8.11(b) with respect to such
license agreement as well as all other obligations of such license agreement that are applicable to
sublicensees thereunder, and (3) DAS acknowledges in writing that its sublicense under such license
agreement is subject to the terms and conditions of such license agreement.

          (c) DAS hereby covenants (unless it receives prior written consent from Sangamo, which Sangamo
shall not unreasonably withhold) that it shall not itself directly license from Third Parties any
intellectual property relating to ZFP Products without first notifying Sangamo in writing of such
Third Party intellectual property and providing Sangamo with a reasonable opportunity to obtain a
license from such Third Party.

ARTICLE 3

OVERVIEW AND MANAGEMENT OF THE COLLABORATION

     3.1 Overview of the Collaboration. Sangamo and DAS will conduct a Research Collaboration
pursuant to the terms and conditions set forth in this Agreement. They will also cooperate in
carrying out the Licensing Program. During the Option Period, DAS may conduct research under its
research license apart from the Research Program, provided DAS shall disclose to Sangamo the
general subject matter (but not necessarily the specific targets) of all such research, and shall
disclose to Sangamo any Improvements or Program Inventions arising from such research.

     3.2 Research Program. The goal of the Research Program will be to validate and optimize the
Sangamo Technology for use in the Field and enable DAS to determine whether it wishes to exercise
the Option.

     3.3 Licensing Program. To the extent that DAS in its discretion decides to pursue the
Licensing Program, the Parties will cooperate to supply ZFP Products to Sublicensees.

     3.4 Overall Management Structure. The management of the Collaboration shall be

 18.

 

vested in a Joint Steering Committee (the “JSC”) and Joint Research Team (the “JRT”), with
responsibilities, as further discussed in Sections 3.5 and 3.6, respectively.

     3.5 Joint Steering Committee.

          (a) Membership. The JSC shall be composed of at least four (4) members, two (2) members
appointed by each Party. The JSC will consist of senior members from each Party authorized to make
decisions with respect to matters including, but not limited to, setting research goals,
determining program expansions, determining the criteria for the special research milestone
payments and when such criteria are met, resolving disputes, and making strategic decisions.
Promptly following the Effective Date, each Party shall appoint its initial representative to the
JSC. Each Party may replace its JSC representatives at any time upon written notice to the other
Party. DAS will designate one of its representatives as the Chairperson of the JSC. The
Chairperson shall be responsible for scheduling meetings, preparing and circulating an agenda in
advance of each meeting, preparing and issuing minutes of each meeting within thirty (30) days
thereafter, revising such minutes to reflect timely comments thereon, and overseeing the
ratification of such revised minutes.

          (b) Meetings. During the Research Term, the JSC shall meet a minimum of one (1) time every
six (6) months. After the Research Term has expired, the JSC shall meet at the request of either
Party, which request may be made by each Party not more than once in each six (6) month period
following the end of the Research Term, unless otherwise agreed to by unanimous consent of all
members of the JSC. The Parties shall endeavor to schedule meetings of the JSC at least six (6)
months in advance. Meetings for the JSC shall be held on an alternating basis in Richmond,
California (or such other location in the continental United States as may be chosen by Sangamo)
and Indianapolis, Indiana (or such other location in the continental United States as may be chosen
by DAS). With the consent of the representatives of each Party serving on a particular committee,
other representatives of each Party may attend meetings of that committee as non-voting observers.
A meeting of the JSC or a subordinate committee may be held by audio or video teleconference with
the consent of each Party, provided that at least half of all meetings for that committee in each
calendar year shall be held in person. Meetings of the JSC or a subordinate committee shall be
effective only if at least one

 19.

 

representative of each Party is present or participating. Each Party shall be responsible for
all of its own expenses of participating in the committee meetings.

          (c) Responsibilities. The JSC shall:

               (i) Manage and direct the implementation of the Agreement with the assistance of the Joint
Research Team as described in Section 3.6;

               (ii) Establish the strategic direction of the Research Program;

               (iii) Oversee and direct the planning and execution of the Research Plan;

               (iv) Evaluate the progress of the Research Program;

               (v) Determine the completion of milestones set forth in Sections 8.4 and 8.5;

               (vi) Review, comment upon and approve any amendments or modifications to the Research Plan
(including, if applicable, the Research Budget) within thirty (30) days of receipt;

               (vii) Have authority to establish one or more other committees that report to the JSC and
assist the JSC in managing and directing the Research Program. Any committees formed beyond the
JSC shall be subordinate to the JSC, shall have such membership and responsibilities as the JSC
shall determine, and may be disbanded by the JSC at any time. Each Party shall use good faith and
cooperative efforts to facilitate and assist the efforts of the JSC and all additional committees
established by the JSC. For clarity, the JSC does not have any authority beyond the specific
matters set forth in this Agreement, and cannot in any way amend or modify the terms or provisions
of this Agreement;

               (viii) Resolve, or attempt to resolve any disputes not resolved by the Joint Research Team or
any other subordinate committees created by the JSC;

               (ix) Perform such other functions as appropriate to further the purposes

 20.

 

of this Agreement and as allocated to it in writing by the Parties; and

               (x) Critically review the results of the Research Program during the first half of the eighth
calendar quarter of the Initial Research Term, to make a finding whether or not the results have
been so disappointing, based for example on consistent failure to achieve the research milestones
set forth in the Research Plan, that exercise of the Option by DAS is highly unlikely.

          (d) Decision Making; Authority. The JSC shall make its decisions by consensus, with each
Party’s representatives collectively having one vote. If the JSC is unable to reach consensus
regarding a matter before it, the issue shall be presented by the JSC to the Chief Executive
Officer of each Party (or his or her designee) (“CEO”) for resolution. Once an issue has been
presented to the CEOs, the CEOs shall have fifteen (15) days to make a final determination
regarding the issue in dispute. In the event that the CEOs are unable to reach a final
determination within such fifteen (15) day period, then the Parties shall present the issue to a
single arbitrator under the rules of the American Arbitration Association applicable to expedited
arbitrations. For clarity, the foregoing shall only apply to issues remaining unresolved by the
JSC pursuant to this Section 3.5(d) and shall not apply to any other dispute arising out of or
relating to this Agreement (including without limitation any disputes regarding a Party’s alleged
breach of this Agreement), which shall instead be resolved pursuant to Section 8.17, 12.6(d) or
14.1. The JSC does not have any authority beyond the specific matters set forth in this Agreement,
and cannot in any way amend or modify the terms or provisions of this Agreement.

     3.6 Joint Research Team

          (a) Membership. The Joint Research Team (JRT) shall consist of at least two (2)
representatives from each Party, with at least one (1) representative from each Party being a
scientist responsible in their respective organizations for day-to-day management of the Research
Program. No more than one (1) member from each Party shall be a member of both the JSC and the
JRT.

          (b) Responsibilities. The JRT shall report to and be subordinate to the JSC. The JRT will
manage implementation of the Research Program, review results of the Research

 21.

 

Program, and suggest changes in the Research Plan or the Research Budget to the JSC when such
changes appear to be advisable to achieve the goals of the Research Program. Upon expiration of
the Research Term, the JSC may dissolve the JRT.

          (c) Meetings. The JRT shall meet at least quarterly, and on a monthly basis shall confer by
telephone conference or video conference, or both, during the Research Term. Each Party shall have
(1) vote. Disputes shall be referred to the JSC, and if they cannot be resolved at that level,
will be resolved in accordance with the procedure described in Section 3.5(d).

     3.7 Collaboration Guidelines.

          (a) General. In all matters related to implementation of the Agreement, the Parties shall be
guided by standards of reasonableness in economic terms and fairness to each of the Parties,
striving to balance the legitimate interests and concerns of the Parties and further the Research
Program.

          (b) Independence. Subject to the terms of this Agreement, the activities and resources of
each Party shall be managed by such Party, acting independently and in its individual capacity.
The relationship between Sangamo and DAS is that of independent contractors and neither Party shall
have the power to bind or obligate the other Party in any manner, other than as is expressly set
forth in this Agreement.

ARTICLE 4

RESEARCH PROGRAM

     4.1 Research Term. The Research Program shall be conducted solely during the Research Term.
Each Party’s obligations under the Research Plan and DAS’s research funding commitments set forth
in Section 8.3 shall remain in force during the Research Term and shall terminate at the end of the
Research Term. The Subsequent Research Term shall end when the Parties agree in writing to
terminate it or are not able to agree upon additional work to be

 22.

 

performed under the Research Plan.

     4.2 Research Plan. The Parties have agreed upon an initial Research Plan, which is set forth
in a separate side letter. Within one hundred and twenty (120) days following the Effective Date,
the JSC shall update and finalize a new version of the Research Plan, which will include a full
description of the events calling for special research milestone payments required by Section 8.4.
During the Research Term, the JSC shall review the Research Plan at least semiannually and may
generate revised versions of the Research Plan that are consistent with the terms of this Agreement
and the goals of the Collaboration. Significant changes in the scope or direction of the work and,
any funding requirements exceeding one hundred fifteen percent (115%) of the Research Budget must
be approved by the JSC. Without such approval, the most recently approved Research Plan shall
remain in effect. Once approved by the JSC, such revised Research Plan shall replace the prior
Research Plan. The Research Plan shall allocate between the Parties responsibility for each of the
Research Program activities described therein in a manner consistent with this Agreement. It is
anticipated that Sangamo shall be primarily responsible for the Manufacture of ZFP Products, and
that DAS shall be primarily responsible for the implementation of the use of ZFP Products in
plants.

     4.3 Use of Subcontractors. Either Party may subcontract portions of the activities allocated
to it under the Research Plan to any of its Affiliates, or to a Third Party, provided that such
Third Party receives the prior approval of the JSC. Notwithstanding the foregoing, the JSC may
expressly waive this requirement with respect to the subcontracting of certain Research Program
activities that both Parties agree should be within the sole discretion of a Party.

     4.4 Reports to JSC. At each meeting of the JSC during the Research Term and the six-month
period following the end of the Research Term, each Party shall submit to the JSC a written
progress report summarizing the work performed under the Research Plan since the last meeting.

     4.5 Conduct of Research Program. The Parties shall use Diligent Efforts to conduct their
respective tasks assigned pursuant to the Research Plan and to attempt to achieve the objectives of
the Research Program efficiently and expeditiously. Each Party shall conduct its portion of the
Research Program in good scientific manner, and in compliance in all material

 23.

 

respects with the requirements of applicable laws, rules and regulations and all applicable
good laboratory practices.

     4.6 Research Funding. DAS shall be solely responsible for supporting the costs of its own
efforts under the Research Plan, including but not limited to all costs and expenses associated
with DAS personnel. DAS shall support Sangamo’s efforts under the Research Plan in the ways
described in Section 8.3.

ARTICLE 5

LICENSING PROGRAM

     5.1 General. DAS shall have the right, but not the obligation for marketing ZFP Products to
Third Parties for use in the Field and for negotiating Technology Licenses with such Third Parties,
all of which shall be carried out at DAS’s sole expense. DAS shall keep Sangamo reasonably
informed regarding all Technology License negotiations. DAS shall provide Sangamo with a copy of
each executed Technology License within thirty (30) days after execution. DAS shall also provide
Sangamo with copies of research licenses that it grants pursuant to Section 2.1(a)(ii) within
thirty (30) days after execution. With respect to any Technology License or research license that
includes a sublicense under a Third Party License that requires Sangamo to provide to the
applicable Third Party licensor a copy of any Technology License or research license or a summary
of the terms of such Technology License or research license, Sangamo shall be permitted to provide
such Third Party licensor with such copy or summary.

     5.2 Technology Licenses. DAS shall ensure that all Technology Licenses comply with the
following requirements:

          (a) No Technology License shall obligate (or purport to obligate) Sangamo, without Sangamo’s
express prior written consent, to any obligation other than Manufacture of ZFP Products under the
terms and conditions set forth in Article 7.

          (b) Each Technology License granted during the Option Period shall require the relevant
Sublicensee to pay milestones and royalties to DAS that are no less than DAS’s

 24.

 

milestone and royalty obligations to Sangamo, as set forth in Sections 8.9 and 8.10, for the
corresponding products arising from such Sublicensee’s activities in the Field.

          (c) Each Technology License shall include provisions permitting DAS, upon termination of this
Agreement, to assign its rights and obligations to Sangamo (or, in the case of Manufacturing
obligations, a Contract Manufacturer, as the case may be) in a manner consistent with the relevant
sections of Article 11.

          (d) Each Technology License shall require the relevant Sublicensee to:

               (i) disclose in a timely fashion to DAS any Improvement(s) made, conceived, or reduced to
practice by the such Sublicensee in its activities under the Technology License; and

               (ii) grant to Sangamo a fully paid, world-wide, irrevocable license under any such
Improvements that is exclusive for uses outside the Field and is fully sublicensable.

          (e) Each Technology License shall identify Sangamo as a third party beneficiary with respect
to the license set forth in Section 5.2(d)(ii).

          (f) Each Technology License shall require that the relevant Sublicensee (i) assume the
obligations set forth in Section 8.11(c) and Exhibit D (as if such Sublicensee were DAS) with
respect to each Third Party License sublicensed thereunder, and (ii) acknowledge that the
Technology License is subject to the terms and conditions of each such Third Party License.

     5.3 DAS Discretion. In recognition of DAS’s Minimum Annual Payment obligation pursuant to
Section 8.7, the Parties agree that:

          (a) DAS has no obligation to seek Sublicensees, and

          (b) following payment of the Option Fee specified in Section 8.6, DAS will have the right to
enter into Technology Licenses and grant research licenses pursuant to Section 2.1(a)(ii), each on
terms that it chooses, subject to the requirements of Sections 5.2 and 5.4, respectively; and will
have no obligation to account to Sangamo for non-cash compensation

 25.

 

received from Sublicensees pursuant to Technology Licenses or research licenses pursuant to
Section 2.1(a)(ii).

     5.4 Research Licenses. DAS shall ensure that all research licenses it grants pursuant to
Section 2.1(a)(ii) comply with the following requirements:

          (a) ownership of any ZFP Product supplied to the Sublicensee shall remain in DAS (as between
DAS and such Sublicensee) and the ZFP Product will be treated as confidential by such Sublicensee;

          (b) the Sublicensee will not transfer any ZFP Product to any other person or entity without
prior written approval of DAS and without such other person or entity entering into a material
transfer agreement with DAS that contains substantially similar terms to those in the research
license with such Sublicensee (and such material transfer agreement shall be considered a research
license granted by DAS pursuant to Section 2.1(a)(ii));

          (c) the Sublicensee’s use of any ZFP Product supplied to it will be limited strictly to
evaluation purposes in the Field;

          (d) commercialization of any products resulting from use of ZFP Products will be prohibited in
the absence of a Technology License;

          (e) Each Research License shall require the relevant Sublicensee to:

               (i) disclose in a timely fashion to DAS all Improvement(s) and Program Inventions made,
conceived, or reduced to practice by the such Sublicensee in its activities under the Research
License to permit consideration of patent strategy by DAS and Sangamo;

               (ii) with respect to any Sublicensee that is an academic or not-for-profit institution, grant
to Sangamo a fully paid, world-wide, irrevocable non-exclusive license under any such Improvements
and Program Inventions for uses outside the Field that is fully sublicensable, with an exclusive
option to negotiate an exclusive commercial license for uses outside the Field; and

 26.

 

               (iii) with respect to any Sublicensee that is not an academic or not-for-profit institution,
grant to Sangamo a fully paid, world-wide, irrevocable exclusive license under any such
Improvements and Program Inventions for uses outside the Field that is fully sublicensable;

          (f) Each Research License shall identify Sangamo as a third party beneficiary with respect to
the licenses set forth in Sections 5.3(e)(ii) and 5.3(e)(iii);

          (g) DAS will have at least thirty (30) days to review, comment on and request removal of
confidential information from any proposed publication reporting results of work with ZFP Products
supplied to a Sublicensee and DAS shall not have the authority, without Sangamo’s prior written
consent, to approve any proposed publication that contains Sangamo Confidential Information;

          (h) such research license shall not obligate (or purport to obligate) Sangamo, without
Sangamo’s express prior written consent, to any obligation other than Manufacture of ZFP Products
under the terms and conditions set forth in Article 7;

          (i) no ZFP Products to which a Third Party License under Section 8.11(b) is applicable will be
supplied to a Sublicensee unless the applicable research license requires that the Sublicensee (i)
assume the obligations set forth in Sections 8.11(c) and 8.11(d) and Exhibit D (as if such
Sublicensee were DAS) with respect to each such Third Party License sublicensed thereunder, and
(ii) acknowledge that the research license is subject to the terms and conditions of each such
Third Party License.

          (j) such research license shall terminate upon the termination of this Agreement for any
reason or the termination of the Licensing Program pursuant to Section 11.5.

ARTICLE 6

DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS

     6.1 DAS Products. Sangamo shall have no responsibility for any costs or expenses incurred by
DAS, its Affiliates, or any sublicensees in undertaking development or

27.

 

commercialization of DAS Products.

     6.2 Trait Sublicensing. DAS may license Third Parties to commercialize DAS ZFP Traits or DAS
Products provided that (a) such Third Party does not have the right to use ZFP Products apart from
such use that is inherent in the ZFP Trait, (b) the applicable agreement with the Third Party does
not obligate (or purport to obligate) Sangamo in any way, and (c) such licenses do not grant any
sublicenses or rights with respect to Sangamo Technology.

ARTICLE 7

MANUFACTURE AND SUPPLY

     7.1 Supply of ZFP Products. Subject to Section 7.2, Sangamo shall be obligated to Manufacture
and supply ZFP Products for use by the Parties and for use by Sublicensees. Quantities and
delivery schedules for all ZFP Products to be used in the Research Program shall be set forth in
the Research Plan. For ZFP Products to be used by Sublicensees, DAS shall negotiate quantities and
delivery schedules for such ZFP Products on a case-by-case basis, provided, however, that such
quantities and delivery schedules are reasonable and further provided that under normal
circumstances (wherein at least *** of relevant target sequence is provided) Sangamo
will deliver ZFP Products within *** (***) weeks of request. For the supply
of ZFP Products to DAS and Sublicensees, Sangamo will directly charge DAS or Sublicensees (as
applicable) a transfer price reflecting solely (i) the cost of time and materials expended in
Manufacturing such ZFP Products, and (ii) a reasonable allocation of overhead expenses and other
indirect costs, where such overhead and indirect costs shall be no greater than charged in similar
circumstances to other customers. The Parties agree that a reasonable estimate for the cost of a
ZFP Product as of the Effective Date is $*** and the cost is expected to go down. DAS,
however, acknowledges and agrees that the time, effort, and cost associated with Sangamo’s
Manufacturing efforts is likely to vary significantly from ZFP Product to ZFP Product and that, as
a result, Sangamo cannot, as of the Effective Date, commit to any particular price, quantity, or
delivery schedule for the supply of ZFP Products. However, Sangamo will work collaboratively with
DAS to establish a structured pricing platform for the supply of ZFP Products.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

28.

 

     7.2 Transfer of Manufacturing Technology. At any time following the end of the Option Period,
DAS may request that Sangamo transfer the Manufacturing technology either to DAS or to a Contract
Manufacturer selected by DAS and approved by Sangamo. Sangamo shall not unreasonably withhold
approval of a Contract Manufacturer selected by DAS. Sangamo shall transfer to DAS or such
Contract Manufacturer, as the case may be, all Information Controlled by Sangamo that is related to
the Manufacturing of ZFP Products for use in the Field and is reasonably necessary or useful to
enable DAS or such Contract Manufacturer (as appropriate) to Manufacture ZFP Products. It is
anticipated that such transfer of Information will be complete within one (1) year after Sangamo’s
receipt of DAS’s request, and Sangamo shall use commercially reasonable efforts to meet this
deadline. The costs and expenses incurred by Sangamo in carrying out such transfer shall be
reimbursed by DAS at the then-current Annual FTE rate.

     7.3 Technology Escrow. Within ninety (90) days of the Effective Date, the Parties agree to
establish, at DAS’ sole expense, a technology escrow that will ensure that computer media
containing the protocols and procedures for Manufacture of ZFP Products that are identified in
Section 12.5(a) will be available to DAS upon occurrence of any of the following events:

          (a) the adjudication of Sangamo as a bankrupt by any court of competent jurisdiction;

          (b) the appointment of a trustee or receiver (or similar official) of all or a substantial
part of the property of Sangamo under the federal Bankruptcy Act or any state court receivership
proceedings, whether voluntary or involuntary, which appointment, if involuntary, is not removed
within sixty (60) days;

          (c) the liquidation of Sangamo or its failure to continue in business (except in the event
that such business has been acquired or assumed by another entity);

          (d) the filing by Sangamo of a voluntary petition in bankruptcy, or the consent to, or failure
to dismiss within the time prescribed by law, of any bankruptcy proceedings instituted against it;
or

29.

 

          (e) Refusal by Sangamo to allocate resources to Manufacture of ordered ZFP Products for a
period of 90 consecutive days or more (unless a Contract Manufacturer is Manufacturing ZFP
Products).

Sangamo will provide written confirmation upon completion of the deposit with the escrow agent.
The technology escrow shall end, and the aforementioned computer media shall be returned to Sangamo
upon the earlier of termination of this Agreement or completion of the Manufacturing technology
transfer described in Section 7.2.

ARTICLE 8

COMPENSATION

     8.1 License Fee. In consideration for the licenses to Sangamo’s patents and know-how set
forth in Article 2 and access to Sangamo’s archives of ZFP Products, DAS shall pay Sangamo a
license fee of seven and a half million dollars ($7,500,000) within thirty (30) days of the
Effective Date. The license fee payment made by DAS to Sangamo pursuant to this Section 8.1 shall
be noncreditable and nonrefundable.

     8.2 Stock Purchase. Upon Sangamo’s request, DAS or a DAS Affiliate will participate in
Sangamo’s next financing by purchasing up to four million dollars ($4,000,000) of Sangamo common
stock (but in no event greater than *** percent (***%) of the total round),
subject to the terms of a separate stock purchase agreement and other agreements and related
documents executed pursuant thereto. This obligation is further contingent on the following
conditions:

          (a) The financing must close no later than October 1, 2006; and

          (b) The total round must be a minimum of 15 million dollars ($15,000,000).

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

30.

 

     8.3 Research Support.

          (a) DAS shall provide six million dollars ($6,000,000) in research support to Sangamo for
research projects carried out by Sangamo pursuant to the Research Plan during the Initial Research
Period; however, this commitment is contingent upon (i) the JSC being able to agree upon research
projects that are commercially and scientifically reasonable and (ii) the Agreement not terminating
pursuant to Section 11.2. DAS will pay Sangamo against invoices for work actually carried out by
Sangamo (based on the current Annual FTE Rate) and expenses incurred by Sangamo that were included
in the Research Budget or otherwise authorized by the JSC in carrying out the Research Program;
however, during the first eight quarters of the Initial Research Term (contract quarters will
correspond to calendar quarters, ending on December 31, March 31, June 30, and September 30), DAS
will advance to Sangamo a minimum of five hundred thousand dollars ($500,000) per quarter, totaling
four million dollars ($4,000,000) for the first eight quarters. More specifically, at the
beginning of each of the first eight quarters, Sangamo will invoice DAS for an advance of five
hundred thousand dollars ($500,000), and DAS will pay such amount within thirty (30) days of
receiving the invoice. The second and subsequent six invoices will each be accompanied with a
description of the services provided and expenses incurred by Sangamo in the previous quarter in
reasonable detail demonstrating the specific basis for the charges. During the eighth quarter, the
JSC will conduct a review of the Research Program pursuant to Section 3.5(c)(x). Unless DAS
terminates this Agreement pursuant to Section 11.2, Sangamo will submit invoices at the end of the
eighth and subsequent quarters, which will each be accompanied with a description of the services
provided and expenses incurred by Sangamo in that quarter in reasonable detail demonstrating the
specific basis for the charges, and DAS will pay Sangamo within thirty (30) days of receiving the
invoice. If the amount advanced by DAS exceeds the services provided and expenses incurred by
Sangamo during the first eight quarters, then the balance will be applied against subsequent
invoices. However, if DAS terminates this Agreement pursuant to Section 11.2, Sangamo will not be
required to refund any excess of the Research Funding advanced by DAS during for the first eight
quarters of the Research Term.

          (b) During the last quarter of the third contract year, and during the last quarter of the
contract year for each subsequent year for so long as the Subsequent Research

31.

 

Term continues, the JSC will determine whether the Subsequent Research Term will be extended
for an additional year. DAS shall provide up to one million dollars ($1,000,000) in research
support to Sangamo during each year of the Subsequent Research Term, however, this commitment is
contingent upon the JSC being able to agree upon research projects that are commercially and
scientifically reasonable.

          (c) Sangamo shall track and calculate the number of Sangamo FTEs involved in the Research
Program using the then-current Annual FTE Rate and in accordance with Sangamo’s then-current
accounting methodology. In no event shall Sangamo be required during the Research Term to incur
more expenses (including FTE-based expenses calculated at the then-current Annual FTE Rate) in the
course of performing its obligations under the Research Plan than the amount that DAS is obligated
to pay Sangamo pursuant to this Section 8.3.

          (d) All research support payments made by DAS to Sangamo pursuant to this Section 8.3 shall be
noncreditable and nonrefundable.

     8.4 Special Research Milestone Payments. Within ninety (90) days of the Effective Date, the
JSC will define events which when achieved will entitle Sangamo to receive a total of four million
dollars ($4,000,000) in special research milestone payments. These event definitions will be
incorporated into the Research Plan. DAS will pay all such special research milestone payments to
Sangamo within thirty (30) days after the earlier of (a) determination by the JSC that the
corresponding event set forth in the Research Plan has been achieved and (b) Sangamo’s receipt of
the Option Exercise Notice. Within thirty (30) days of a request by either Party, the JSC shall
hold a meeting by audio or video conference to make such a determination. In no event will the
total amount of special research milestone payments paid by DAS pursuant to this Section 8.4 exceed
four million dollars ($4,000,000). If the special research milestone payments made by DAS prior to
Sangamo’s receipt of the Option Exercise Notice total less than four million dollars ($4,000,000),
then the balance will be paid to Sangamo thirty (30) days after Sangamo’s receipt of the Option
Exercise Notice. All special research milestone payments made by DAS to Sangamo pursuant to this
Section 8.4 shall be noncreditable and nonrefundable.

32.

 

     8.5 *** Milestone Payments.

          (a) Within thirty (30) days after the first satisfaction of a *** for a DAS
Product, DAS shall pay Sangamo one million dollars ($1,000,000). This is a one time payment, and
DAS shall in no case be obligated to make this payment more than once.

          (b) On the first anniversary of the first Full-scale Product Launch for a DAS Product that
satisfies a ***, DAS shall pay Sangamo two million dollars ($2,000,000). This is a one
time payment and DAS shall in no case be obligated to make this payment more than once

          (c) All *** milestone payments made by DAS to Sangamo pursuant to this Section 8.5
shall be noncreditable and nonrefundable.

          (d) The payments called for in this Section 8.5 are in lieu of the Product Milestone Payments
called for in Section 8.9(b) for the first ***.

     8.6 Option Fee. DAS shall pay Sangamo an option fee of six million dollars ($6,000,000)
within thirty (30) days after it provides the Option Exercise Notice. The option fee payment made
by DAS to Sangamo pursuant to this Section 8.6 shall be noncreditable and nonrefundable.

     8.7 Minimum Annual Payments.

          (a) If DAS exercises the Option, then DAS shall pay to Sangamo within thirty (30) days of each
anniversary of the Effective Date starting with the third anniversary of the Effective Date, the
Minimum Annual Payment obligation set forth in this Section 8.7 for the calendar year in which such
anniversary occurs. The Minimum Annual Payment obligation for the calendar years in which the
3rd through 6th anniversaries occur are as follows:

	 	 	 	 	 	 	 	 	 
	Anniversary of the Effective Date	 	 	 	 	 	Minimum Annual Payment Obligation
	Third (October 1, 2008)
	 	 	 	 	 	$	***	 
	Fourth (October 1, 2009)
	 	 	 	 	 	$	***	 
	Fifth (October 1, 2010)
	 	 	 	 	 	$	***	 
	Sixth (October 1, 2011)
	 	 	 	 	 	$	***	 

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

33.

 

The Minimum Annual Payment Obligation for each calendar year in which the seventh and subsequent
anniversaries of the Effective Date occur, until the earlier of (i) DAS’s termination of the
Licensing Program pursuant to Section 11.5, (ii) the expiration of this Agreement pursuant to
Section 11.1, or (iii) the termination of this Agreement pursuant to Section 11.4 or 11.6, shall be
*** dollars (US $***)

          (b) In each calendar year in which DAS has a Minimum Annual Payment Obligation, it will pay
Sangamo, an amount equal to the applicable Minimum Annual Payment Obligation, less any Sublicensing
Revenues paid to Sangamo for Sublicensing Revenues received by DAS during the first two quarters of
the calendar year in which the Minimum Annual Payment is due. The amount due will be invoiced by
Sangamo as of October 1st, and DAS shall pay Sangamo within thirty (30) days of receiving the
invoice. Each payment made by DAS pursuant to this Section 8.7 is referred to as a Minimum Annual
Payment.

          (c) Each Minimum Annual Payment made by DAS to Sangamo pursuant to this Section 8.7 shall be
nonrefundable but fully creditable against the following:

               (i) the Sublicensing Revenue payments pursuant to Section 8.8 due for the third and fourth
quarters of the calendar year in which such Minimum Annual Payment was made; and

               (ii) the DAS Product Royalties pursuant to Section 8.10 due to Sangamo for the calendar year
in which such Minimum Annual Payment was made.

          (d) Example of Operation of Minimum Annual Payment. Accordingly, for example, if DAS is
assumed to have paid Sangamo $50,000 for Sublicensing Revenues received in the first two quarters
of 2009, a year in which the Minimum Annual Payment obligation is$***, DAS would owe
Sangamo a Minimum Annual Payment of $***– $50,000 = $***, which Sangamo
would invoice as of October 1, 2009. DAS’s $*** Minimum Annual Payment would be
creditable against additional Sublicensing Revenues received during the third and fourth quarter
and against the DAS Product Royalties due for the 2009 calendar year.

 

			
	***	 	Certain information on the page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

34.

 

     8.8 Sublicensing Revenues.

          (a) Within thirty (30) days after the end of each calendar quarter during the Option Period,
DAS shall pay Sangamo an amount equal to twenty-five percent (25%) of the Sublicensing Revenues
received by DAS during such calendar quarter. The Sublicensing Revenue payments made by DAS to
Sangamo pursuant to this Section 8.8(a) shall be noncreditable and nonrefundable.

          (b) Within thirty (30) days after the end of each calendar quarter after the end of the Option
Period, DAS shall pay Sangamo an amount equal to twenty-five percent (25%) of the Sublicensing
Revenues received by DAS during such calendar quarter. The Sublicensing Revenue payments made by
DAS to Sangamo pursuant to this Section 8.8(b) shall be noncreditable (except as set forth in
Section 8.7) and nonrefundable.

          (c) Each Sublicensing Revenue payment shall be accompanied by a statement itemizing the amount
and type (e.g., license fee, milestone payment, royalty payment) of each payment received by DAS
from each Sublicensee during the relevant calendar quarter.

8.9 DAS Product Milestone Payments

          (a) Subject to Sections 8.9(c), 8.9(d), 8.9(e) and 8.9(f), for each GMO Product, DAS shall
make the milestone payments set forth below to Sangamo within thirty (30) days after the
achievement of each of the following events:

               (i) *** dollars ($***)upon first filing for Regulatory Approval for such
GMO Product;

               (ii) *** dollars ($***)upon first receipt of Regulatory Approval for
such GMO Product; and

               (iii) ***dollars ($***)upon the first anniversary of the Full-scale
Product Launch for such GMO Product.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

35.

 

          (b) Subject to Sections 8.9(c), 8.9(d), 8.9(e) and 8.9(f), for each Non-GMO Product, DAS shall
make the milestone payments set forth below to Sangamo within thirty (30) days after the
achievement of each of the following events:

               (i) *** dollars ($***)upon first seeking ***for
such***;

               (ii) ***dollars ($***)upon satisfaction of *** for such
***; and

               (iii) ***dollars ($***)upon the first anniversary of the Full-scale
Product Launch for such***.

          (c) The series of product milestone payments specified in Sections 8.9(a) or 8.9(b) will be
applicable for each Major Crop in which a given Trait is inserted, but product milestone payments
under this Section 8.9 will not apply to (i) insertions of a Trait in any crop other than a Major
Crop to the extent that product milestone payments have already been made for that Trait under
Section 8.9(a) or 8.9(b), or (ii) subsequent insertions of a Trait in a particular Major Crop to
the extent that product milestone payments were previously made for insertion of that Trait in that
Major Crop.

          (d) product milestone payments applicable to a Stacking Crop Product will be ***
percent (***%) of those specified in Sections 8.9(a) and 8.9(b).

          (e) ***Products, ***Products, and ***Products will not bear
product milestone payments.

          (f) The applicability and amount, if any, of product milestone payments for any Licensed
Product that does not fall within the definitions of Crop Product, Animal Health Product, Human
Health Product, and Industrial Product will be determined pursuant to Section 8.17.

          (g) All DAS Product milestone payments made by DAS to Sangamo pursuant to this Section 8.9
shall be noncreditable and nonrefundable.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

36.

 

     8.10 DAS Product Royalties.

          (a) Crop Products. DAS shall pay royalties to Sangamo at the rate of (i) ***
percent (***%) of Net Average Trait Value of each Trait Crop Product and (ii)
*** percent (***%)of Net Average Trait Value of each Stacking Crop Product.
For each Crop Product for which the Net Average Trait Value is not determinable (because consumers
are unwilling to pay separately for it, e.g. drought tolerance), but the applicable Trait will help
preserve or expand sales, DAS shall pay Sangamo $*** per acre of Crop Product (this is
equivalent, for example, to $*** per unit of corn, $*** per bag of canola,
and $*** per bag of cotton).

          (b) Animal Health Products. DAS shall pay royalties to Sangamo at the rate of ***
percent (***%) of Net Sales of each Animal Health Product (including Food Safety
Products).

          (c) Industrial Products. DAS shall pay royalties to Sangamo at the rate of ***
percent (***%) of Net Sales of each Industrial Product.

          (d) Human Health Products. DAS shall pay royalties to Sangamo at the rate of
***percent (*** %) of Net Sales of each Human Health Product.

          (e) Other Licensed Products. The applicability and rate, if any, of product royalty for any
Licensed Product that does not fall within the definitions of Crop Product, Animal Health Product,
Human Health Product, and Industrial Product will be determined pursuant to Section 8.17.

          (f) All royalties due under this Section 8.10 shall be paid annually, on a country-by-country
basis, within sixty (60) days of the end of the relevant year for which royalties are due. Such
royalty payments shall be nonrefundable and shall not be creditable against future Minimum Annual
Payments.

          (g) Sangamo’s right to receive royalties under this Section 8.10 shall expire on a
product-by-product and country-by-country basis upon expiration of the last to expire

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

37.

 

Sangamo Patent that claims the DAS Product or the ZFP Product used in the creation of such DAS
Product or in the manufacture, use or sale of such DAS Product or ZFP Product.

          (h) Notwithstanding Section 8.10(g), DAS will pay a royalty to Sangamo under this Section 8.10
for sales in any foreign country where Sangamo lacks patent protection until expiration of the last
to expire U.S. Sangamo Patent that claims the DAS Product or the ZFP Product used in the creation
of such DAS Product or in the manufacture, use or sale of such DAS Product or ZFP Product.
However, if a Third Party enters the market in that foreign country with a product that (i) was
created or made using a ZFP Product, and (ii) contains a competing Trait in the same crop as such
DAS Product, then the royalty rate for sales of that DAS Product will be reduced by
***percent ***%) in that country for so long as such Third Party continues to
market such product in such country.

          (i) Each royalty payment shall be accompanied by a statement that includes sufficient
information for Sangamo to understand DAS’s calculation of such royalty payment, including without
limitation the number, description, and aggregate Net Average Trait Value or Net Sales, by country,
of each DAS Product sold during the relevant calendar year.

          (j) Royalties on Trait License Revenue. When DAS licenses a DAS ZFP Trait to Third Parties,
DAS will report the cash consideration received from the licensees for such DAS ZFP Trait and/or
Licensed Products containing such DAS ZFP Trait, and shall pay royalties to Sangamo on such
consideration, as if it were Net Average Trait Value or Net Sales (as applicable), at the rate set
forth in this Section 8.10 for the applicable product category. DAS shall continue to have the
obligations set forth in Section 8.11 with respect to such Licensed Products as if such products
were DAS Products.

     8.11 Payments for Third Party Licenses.

          (a) Third Party Licenses in Effect on Effective Date. Sangamo (and not DAS) shall be
responsible for paying all milestones, royalties and other compensation owed to Third Parties
pursuant to Third Party Licenses identified in Exhibit C as of the Effective Date

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

38.

 

(including any post Effective Date amendments of such Third Party Licenses) on account of the
generation, development and/or commercialization of Licensed Products by DAS, its Affiliates and
sublicensees and the sale at cost by DAS or its Affiliates of ZFP Products Manufactured by DAS or
its Affiliates. DAS shall provide and shall require its Affiliates and sublicensees to provide
Sangamo, at least ten (10) days in advance of the applicable due date, with all information
reasonably required by or useful to Sangamo to (i) ascertain when milestone payments are owed under
Third Party Licenses, (ii) calculate the amounts of royalty payments due under Third Party
Licenses, and (iii) provide required reports.

          (b) Third Party Licenses First Entered into after the Effective Date. DAS shall be
responsible for paying all milestones, royalties and other compensation owed to Third Parties
pursuant to Third Party Licenses entered into after the Effective Date (and licensed to DAS
pursuant to Section 2.6(b)) on account of the generation, development and/or commercialization of
DAS Products by DAS, its Affiliates and sublicensees and the sale at cost by DAS or its Affiliates
of ZFP Products Manufactured by DAS or its Affiliates. DAS shall pay to Sangamo such amounts owed
to Third Parties pursuant to Third Party Licenses and shall provide Sangamo with any corresponding
reports at least ten (10) days in advance of the applicable due date. Provided it receives such
items in a timely manner, Sangamo shall pay such amounts to, and file such reports with, the
applicable Third Party on or before the applicable due date.

          (c) Licensing Program. Unless otherwise agreed in writing, DAS shall structure each
Technology License so that the Sublicensee shall be responsible for paying all milestones,
royalties and other compensation owed to Third Parties pursuant to Third Party Licenses referred to
in Section 8.11(b) on account of the generation, development and/or commercialization of Licensed
Products arising from such Sublicensee’s activities in the Field. DAS shall collect the relevant
payments and reports from Sublicensees and shall pay to Sangamo all amounts owed to Third Parties
pursuant to Third Party Licenses referred to in Section 8.11(b) and shall provide Sangamo with any
corresponding reports at least ten (10) days in advance of the applicable due date. Provided it
receives such items in a timely manner, Sangamo shall pay such amounts to, and file such reports
with, the applicable Third Party on or before the applicable due date.

39.

 

          (d) Sublicense Issuance and Maintenance Fees. DAS shall be responsible for all sublicense
issuance and maintenance fees owed to Third Parties pursuant to Third Party Licenses referred to in
Section 8.11(b) on account of DAS’s licenses in Section 2.1. Each Sublicensee shall be responsible
for all sublicense issuance and maintenance fees owed to Third Parties pursuant to Third Party
Licenses referred to in Section 8.11(b) on account of such Sublicensee’s Technology License. DAS
shall collect such payments from such Sublicensees and shall pay such amounts, plus the amounts due
on account of DAS’s licenses in Section 2.1, to Sangamo at least ten (10) days before the
applicable due date.

          (e) Upfront Fees. Unless otherwise agreed in writing, the Parties shall share ***
any upfront fees associated with Third Party Licenses referred to in Section 8.11(b).

     8.12 Payment Method. All payments due under this Agreement to Sangamo shall be made by bank
wire transfer in immediately available funds to an account designated by Sangamo. All payments
hereunder shall be made in United States dollars.

     8.13 Taxes. Sangamo shall pay any and all taxes levied on account of all payments it receives
under this Agreement. If laws or regulations require that taxes be withheld, DAS will (i) deduct
those taxes from the remittable payment, (ii) pay the taxes to the proper taxing authority, and
(iii) send evidence of the obligation together with proof of tax payment to Sangamo within thirty
(30) days following that tax payment.

     8.14 Foreign Exchange. Conversion of sales recorded in local currencies to United States
dollars will be performed in a manner consistent with DAS’s normal practices used to prepare its
audited financial statements for internal and external reporting purposes, which uses a widely
accepted source of published exchange rates.

     8.15 Records; Inspection. DAS shall keep complete, true and accurate books of account and
records for the purpose of determining the payments to be made under this Agreement. Such books
and records shall be kept for at least three (3) years following the end of the calendar quarter to
which they pertain. Such records will open for inspection during such

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

40.

 

three (3) year period by independent accountants, solely for the purpose of verifying payment
statements hereunder. Such inspections shall be made no more than once each calendar year, at
reasonable time and on reasonable notice. Inspections conducted under this Section 8.15 shall be
at the expense of Sangamo, unless a variation or error producing an increase exceeding five percent
(5%) of the amount paid for any period covered by the inspection is established in the course of
such inspection, whereupon all costs relating to the inspection for such period will be paid
promptly by DAS. DAS shall promptly pay to Sangamo any unpaid amounts (plus interest) that are
discovered as a result of an inspection hereunder.

     8.16 Interest. If DAS fails to make any payment due to Sangamo under this Agreement, then
interest shall accrue on a daily basis at a rate equal to *** percent (***%)
above the then-applicable prime commercial lending rate of CitiBank, N.A. San Francisco,
California, or at the maximum rate permitted by applicable law, whichever is the lower.

     8.17 Negotiation of Compensation for Other Licensed Products. In the event that DAS develops
a Licensed Product that does not fall within the definitions of Crop Product, Animal Health
Product, Human Health Product, or Industrial Product, the Parties will discuss in good faith an
amendment to this Agreement to provide a fair and reasonable financial return to Sangamo based on
industry norms for that type of product, which return may include product milestone payments and
product royalty payments. Such discussions will be initiated before DAS advances the Licensed
Product from its discovery research phase to its product development phase. If the Parties are
unable to agree on the applicability or amounts of such payments, the dispute will be referred,
upon written notice by either Party, to the CEOs. Within twenty (20) days after such notice, the
CEOs shall meet for attempted resolution by good faith negotiations. If the CEOs are unable to
resolve such dispute within thirty (30) days of their first meeting for such negotiations, then
either Party may seek to have such dispute finally settled by a single arbitrator under the rules
of the American Arbitration Association applicable to expedited arbitrations. The amounts to be
paid by DAS to Sangamo with respect to the development and commercialization of a Licensed Product
to which this Section 8.17 pertains shall be agreed upon by the Parties or resolved by the dispute
resolution procedures set forth

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

41.

 

herein and set forth in an amendment to this Agreement prior to the first commercial sale of
such Licensed Product. DAS shall refrain from making such a first commercial sale until such
amendment is executed by both Parties.

ARTICLE 9

INTELLECTUAL PROPERTY

9.1 Disclosure of Inventions; Ownership of Intellectual Property.

          (a) At a regular interval to be agreed by the Parties (but no less than two times per year),
the Parties shall disclose to each other the making, development, conception, or reduction to
practice of all Improvements, Product Specific Inventions, and Program Inventions, to extent that
any of the foregoing were made, developed, conceived, or reduced to practice since the previous new
invention disclosure.

          (b) Ownership of the Sangamo Know-How and Sangamo Patents shall be and remain vested at all
times in Sangamo.

          (c) DAS shall own any Product Specific Invention that relates to a DAS Product.

          (d) DAS Improvements and DAS Improvement Patents shall be owned by DAS (subject to Sangamo’s
world-wide, royalty-free, exclusive license for all uses outside the Field, including the right to
sublicense, which it shall have pursuant to Section 2.3(b)).

          (e) Joint Inventions and Joint Patents shall be jointly owed by DAS and Sangamo, with each
Party having an undivided one-half interest in each Joint Invention and Joint Patent. Each Party
may practice and grant licenses under each Joint Invention and Joint Patent without the consent of,
or a duty of accounting to, the other Party, provided that such practice and licenses are
consistent with such Party’s rights under this Agreement. Without limiting the generality of the
foregoing, DAS’s rights in the Joint Inventions and Joint Improvements shall be subject to
Sangamo’s world-wide, royalty-free, exclusive license for all uses outside the Field,

42.

 

including the right to sublicense, which it shall have pursuant to Section 2.3(b).

          (f) Ownership of Improvements made by Sublicensees pursuant to Technology Licenses will be
governed by the applicable Technology License, but shall in every case be subject to Sangamo’s
world-wide, royalty-free, exclusive license for all uses outside the Field, including the right to
sublicense, which it shall have pursuant to Section 5.2(d).

          (g) Program Inventions and Program Patents (other than Joint Program Inventions and Joint
Program Patents, which are addressed in Section 9.1(e)) shall be owned in accordance with
inventorship, subject to the licenses the Parties have granted to each other pursuant to this
Agreement.

     9.2 Employees; Cooperation.

          (a) Each Party represents and agrees that all employees or others acting on its behalf in
performing its obligations under this Agreement shall be obligated under a binding written
agreement to assign to such Party all inventions (and all related intellectual property) made or
conceived by such employee or other person during and in connection with the Collaboration. The
Parties agree to undertake to enforce such agreements (including, where appropriate, by legal
action) considering, among other things, the commercial value of such inventions.

          (b) The Party responsible for filing, prosecution, or maintenance of a particular
Field-Specific Sangamo Patent, Program Patent, or Improvement Patent pursuant to Section 9.3(b)(i),
9.4, or 9.5 (the “Filing Party”) shall consult with and keep other Party (the “Non-Filing Party”)
fully informed of all issues relating to the preparation, filing, prosecution and maintenance of
such patent, and shall furnish to the Non-Filing Party copies of all documents received from, and
filed in, the applicable Patent Office. The Filing Party shall provide to the Non-Filing Party
copies of documents relevant to such preparation, filing, prosecution or maintenance in sufficient
time prior to filing such document or making any payment due thereunder to allow for review and
comment by the Non-Filing Party, and the Filing Party shall consider such comments in good faith.

     9.3 Filing, Prosecution and Maintenance of Sangamo Patents.

43.

 

          (a) Except as set forth in Section 9.3(b), Sangamo shall, as between the Parties, have the
sole right to file, prosecute, and/or maintain the Sangamo Patents, including Sangamo Program
Patents, at its sole discretion, for which it shall bear all associated costs and expenses.

          (b) Solely following the end of the Option Period (but ending upon the termination of this
Agreement), the following rights and obligations shall apply:

               (i) As between the Parties, DAS shall have the first right to file, prosecute, and/or maintain
all Field Specific Sangamo Patents, for which it shall bear all associated costs and expenses. DAS
shall have the right to select the countries in which it files, continues to prosecute, or maintain
the Field Specific Sangamo Patents. Should DAS decide not to file or continue prosecuting or
maintaining a particular Field Specific Sangamo Patent, it shall notify Sangamo in writing promptly
after such decision is made and not less than sixty (60) days prior to any applicable deadline.
Thereafter, Sangamo shall have the right, but not the obligation, to assume such filing,
prosecution and maintenance at its sole cost and expense.

               (ii) As between the Parties, Sangamo shall have the first right to file, prosecute, and/or
maintain all Generally Applicable Sangamo Patents, for which it shall bear all associated costs and
expenses. Sangamo shall use commercially reasonable efforts to conduct its filing and prosecution
of Generally Applicable Sangamo Patents so as to obtain broad patent protection in the Field where
commercially reasonable and available. Should Sangamo decide not to file or continue prosecuting
or maintaining a particular Generally Applicable Sangamo Patent, it shall notify DAS in writing
promptly after such decision is made and not less than sixty (60) days prior to any applicable
deadline. Thereafter, to the extent that no Third Party has a right to assume the prosecution and
maintenance of such Generally Applicable Sangamo Patent, DAS may assume such prosecution and
maintenance at its sole cost and expense.

          (c) DAS’s rights under this Section 9.3 with respect to any Sangamo Patent licensed to Sangamo
by a Third Party shall be subject to the rights of such Third Party to file, prosecute, and/or
maintain such Sangamo Patent.

44.

 

     9.4 Filing, Prosecution and Maintenance of DAS Improvement Patents and DAS Program Patents.
DAS shall have the first right to file, prosecute, and/or maintain all DAS Improvement Patents and
DAS Program Patents, for which it shall bear all associated costs and expenses. Should DAS decide
not to file or continue prosecuting or maintaining a particular DAS Program Patent or DAS
Improvement Patent, it shall notify Sangamo in writing promptly after such decision is made and not
less than sixty (60) days prior to any applicable deadline. Thereafter, Sangamo shall have the
right, but not the obligation, to assume such filing, prosecution and maintenance at its sole cost
and expense.

     9.5 Filing, Prosecution and Maintenance of Joint Patents.

          (a) Sangamo shall have the first right to file, prosecute, and/or maintain all Joint Patents
(including Joint Program Patents and Joint Improvement Patents), the claims of which are not
specific to the Field, for which it shall bear all associated costs and expenses. Should Sangamo
decide not to file or continue prosecuting or maintaining a particular Joint Patent, it shall
notify DAS in writing promptly after such decision is made and not less than sixty (60) days prior
to any applicable deadline. Thereafter, DAS shall have the right, but not the obligation, to
assume such filing, prosecution and maintenance at its sole cost and expense.

          (b) DAS shall have the first right to file, prosecute, and/or maintain all Joint Patents
(including Joint Program Patents and Joint Improvement Patents), the claims of which are specific
to the Field, for which it shall bear all associated costs and expenses. Should DAS decide not to
file or continue prosecuting or maintaining any such patent, it shall notify Sangamo in writing
promptly after such decision is made and not less than sixty (60) days prior to any applicable
deadline. Thereafter, Sangamo shall have the right, but not the obligation, to assume such filing,
prosecution and maintenance at its sole cost and expense.

9.6 Enforcement and Defense of Sangamo Patents

          (a) If either Party becomes aware of any Third Party activity in the Field that infringes a
Sangamo Patent, or any allegation by a Third Party that a Sangamo Patent is invalid or
unenforceable (collectively, for the purpose of this Section 9.6, “Infringement”), then that Party
shall give prompt written notice to the other Party regarding such Infringement.

45.

 

          (b) With respect to any Infringement of a Generally Applicable Sangamo Patent:

               (i) As between the Parties, Sangamo shall have the first right, but not the obligation, to
attempt to resolve such Infringement by commercially appropriate steps, including without
limitation the filing of an infringement suit using counsel of its own choice.

               (ii) If Sangamo fails to resolve such Infringement or to initiate or defend a suit with
respect thereto within one hundred twenty (120) days after delivery of the notice set forth in
Section 9.6(a), then upon DAS’s request and Sangamo’s written consent (not to be unreasonably
withheld), DAS shall have the right, but not the obligation, to attempt to resolve such
Infringement by commercially appropriate steps, including without limitation the filing of an
infringement suit using counsel of its own choice. If DAS institutes such a suit with respect to a
Generally Applicable Sangamo Patent designated as a Core Sangamo Patent, it shall have the right to
set off twenty-five percent (25%) of its litigation costs directly associated with such action
against any payments owed to Sangamo.

          (c) With respect to any Infringement of a Field Specific Sangamo Patent:

               (i) DAS shall have the right, but not the obligation, to attempt to resolve such Infringement
by commercially appropriate steps, including without limitation the filing of an infringement suit
using counsel of its own choice, but only to the extent that Sangamo would otherwise have the right
to enforce such Field Specific Sangamo Patent.

               (ii) If DAS fails to resolve such Infringement or to initiate or defend a suit with respect
thereto within one hundred twenty (120) days after delivery of the notice set forth in Section
9.6(a), then Sangamo shall have the right, but not the obligation, to attempt to resolve such
Infringement by commercially appropriate steps, including without limitation the filing of an
infringement suit using counsel of its own choice.

          (d) In any event, the Party not bringing an infringement action under this Section 9.6 agrees
to be joined as a party to the suit, at the request and expense of the Party bringing such action,
and to provide reasonable assistance in any such action, at the requesting Party’s expense.
Neither Party shall settle or otherwise compromise any such action in a way

46.

 

that adversely affects the other Party’s intellectual property rights without such Party’s
prior written consent.

          (e) Any amounts recovered by the Party taking an action pursuant to this Section 9.6, whether
by settlement or judgment, shall be allocated first to reimburse the Party taking such action for
any costs and expenses incurred and, second, to reimburse Sangamo for any set offs taken by DAS,
pursuant to subsection (b)(ii) above, against payments otherwise due to Sangamo. Any remaining
recovery shall be shared by the Parties in proportion to the percentage of litigation expenses
funded by each Party. Any set offs taken by DAS pursuant to subsection (b)(ii) above shall be
treated as a funding of litigation expenses by Sangamo.

          (f) DAS’s rights under this Section 9.6 with respect to any Sangamo Patent licensed to Sangamo
by a Third Party shall be subject to the rights of such Third Party to enforce such Sangamo Patent
and/or defend against any claims that such Sangamo Patent is invalid or unenforceable.

     9.7 Enforcement and Defense of DAS Improvement Patents and DAS Program Patents

          (a) If either Party becomes aware of any Third Party activity that infringes a DAS Improvement
Patent or DAS Program Patent or any allegation by a Third Party that such a DAS Improvement Patent
or DAS Program Patent is invalid or unenforceable, then that Party shall give prompt written notice
to the other Party regarding such infringement.

          (b) With respect to infringement involving Third Party activity outside the Field or any
allegation that a DAS Improvement Patent or DAS Program Patent is invalid or unenforceable (subject
to Section 9.7(d)), DAS shall have the first right, but not the obligation, to attempt to resolve
such infringement or allegation, whether by settlement or judgment. If DAS fails to resolve such
infringement or to initiate or defend a suit with respect thereto within one hundred twenty (120)
days after delivery of the notice set forth in Section 9.7(a), then Sangamo shall have the right,
but not the obligation, to attempt to resolve such infringement by commercially appropriate steps,
including without limitation the filing of an infringement suit using counsel of its own choice.

47.

 

          (c) With respect to infringement involving Third Party activity solely in the Field, DAS shall
have the right, but not the obligation, to attempt to resolve such infringement or allegation,
whether by settlement or judgment.

          (d) A Party’s right to initiate a patent infringement suit under this Section 9.7 shall
include the right to resolve any allegation that a Improvement Patent is invalid or unenforceable
brought as a counterclaim in such suit.

          (e) In any event, the Party not bringing an infringement action under this Section 9.7 agrees
to be joined as a party to the suit, at the request and expense of the Party bringing such action,
and to provide reasonable assistance in any such action, at the requesting Party’s expense.
Neither Party shall settle or otherwise compromise any such action in a way that adversely affects
the other Party’s intellectual property rights without such Party’s prior written consent.

          (f) Any amounts recovered by the Party taking an action pursuant to Section 9.7(b), whether by
settlement or judgment, shall be allocated first to reimburse the Party taking such action for any
costs and expenses incurred and, any remaining recovery shall be shared by the Parties in
proportion to the percentage of litigation expenses funded by each Party.

     9.8 Enforcement and Defense of Joint Patents.

          (a) If either Party becomes aware of any Third Party activity that infringes a Joint Patent,
or any allegation by a Third Party that a Joint Patent is invalid or unenforceable, then that Party
shall give prompt written notice to the other Party regarding such infringement.

          (b) With respect to infringement of a Joint Patent involving Third Party activity outside the
Field:

               (i) Sangamo shall have the right, but not the obligation, to attempt to resolve such
infringement by commercially appropriate steps, including without limitation the filing of an
infringement suit using counsel of its own choice. If Sangamo institutes such a suit with respect
to a Joint Patent, it will do so at its expense, and will be entitled to keep all recoveries.

48.

 

               (ii) If Sangamo fails to resolve such infringement or to initiate or defend a suit with
respect thereto within one hundred twenty (120) days after delivery of the notice set forth in
Section 9.8(a), then DAS shall have the right, but not the obligation, to attempt to resolve such
infringement by commercially appropriate steps, including without limitation the filing of an
infringement suit using counsel of its own choice. If DAS initiates such a suit with respect to a
Joint Patent it will do so at its own expense, and will be entitled to keep all recoveries.

          (c) With respect to infringement of a Joint Patent involving Third Party activity in the Field
or any allegation that a Joint Patent is invalid or unenforceable (subject to Section 9.8(d)):

               (i) DAS shall have the right, but not the obligation, to attempt to resolve such infringement
or allegation by commercially appropriate steps, including without limitation the filing of an
infringement suit using counsel of its own choice. If DAS institutes such a suit with respect to a
Joint Patent, it will do so at its expense, and will be entitled to keep all recoveries.

               (ii) If DAS fails to resolve such infringement or allegation or to initiate or defend a suit
with respect thereto within one hundred twenty (120) days after delivery of the notice set forth in
Section 9.8(a), then Sangamo shall have the right, but not the obligation, to attempt to resolve
such infringement by commercially appropriate steps, including without limitation the filing of an
infringement suit using counsel of its own choice. If Sangamo initiates such a suit with respect
to a Joint Patent it will do so at its own expense, and will be entitled to keep all recoveries.

          (d) Notwithstanding Section 9.8(c), a Party’s right to initiate a patent infringement suit
under this Section 9.8 shall include the right to resolve any allegation that a Joint Patent is
invalid or unenforceable brought as a counterclaim in such suit.

          (e) In any event, the Party not bringing an infringement action under this Section 9.8 agrees
to be joined as a party to the suit, at the request and expense of the Party bringing such action,
and to provide reasonable assistance in any such action, at the requesting

49.

 

Party’s expense. Neither Party shall settle or otherwise compromise any such action in a way
that adversely affects the other Party’s intellectual property rights without such Party’s prior
written consent.

     9.9 Defense of Third Party Infringement Claims. If a Third Party asserts that a patent or
other right Controlled by it is infringed by activities in the Field or a Party becomes aware of a
patent or other right that might form the basis for such a claim, the Party first obtaining
knowledge of such a claim or such potential claim shall immediately provide the other Party with
notice thereof and the related facts in reasonable detail. The Parties shall discuss the merits of
such claim or potential claims and shall attempt in good faith to mutually agree whether to obtain
a license from such Third Party and whether to make any modifications to the Research Plan or the
Licensing Program. If the intellectual property pertains to ZFP Products both inside and outside
the Field, then, as between the Parties, Sangamo shall be the party that enters into any license
agreement with such Third Party and DAS shall be entitled to a sublicense in the Field under such
license agreement (or any license agreement entered into by Sangamo hereunder that pertains to ZFP
Products in the Field) if it follows the procedures therefor set forth in Section 2.6(b). Neither
Party shall be required to conduct any work under this Agreement which it believes in good faith
may infringe Third Party patent or other intellectual property rights. Except as set forth in
Article 13 or otherwise agreed in writing by the Parties, each Party shall control and bear the
expense of its own defense of such Third Party claim.

ARTICLE
10

CONFIDENTIALITY

     10.1 Nondisclosure of Confidential Information. All Information disclosed by one Party to the
other Party pursuant to this Agreement shall be “Confidential Information” for all purposes
hereunder. The Parties agree that during the term of this Agreement and for a period of seven (7)
years thereafter, a Party receiving Confidential Information of the other Party will (i) use
commercially reasonable efforts to maintain in confidence such Confidential Information (but not
less than those efforts as such Party uses to maintain in confidence its own proprietary industrial
information of similar kind and value) and not to disclose such Confidential

50.

 

Information to any Third Party without prior written consent of the other Party, except for
disclosures made in confidence to any Third Party under terms consistent with this Agreement and
made in furtherance of this Agreement or of rights granted to a Party hereunder, and (ii) not use
such other Party’s Confidential Information for any purpose except those permitted by this
Agreement (it being understood that this subsection (ii) shall not create or imply any rights or
licenses not expressly granted under Article 2).

     10.2 Exceptions. The obligations in Section 10.1 shall not apply with respect to any portion
of the Confidential Information that the receiving Party can show by competent written proof:

          (a) Is publicly disclosed by the disclosing Party, either before or after it is disclosed to
the receiving Party hereunder; or

          (b) Was known to the receiving Party or any of its Affiliates, without obligation to keep it
confidential, prior to disclosure by the disclosing Party; or

          (c) Is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party
lawfully in possession thereof and without obligation to keep it confidential; or

          (d) Is published by a Third Party or otherwise becomes publicly available or enters the public
domain, either before or after it is disclosed to the receiving Party; or

          (e) Has been independently developed by employees or contractors of the receiving Party or any
of its Affiliates without the aid, application or use of Confidential Information.

     10.3 Authorized Disclosure. A Party may disclose the Confidential Information belonging to
the other Party to the extent such disclosure is reasonably necessary in the following instances:

          (a) Disclosures required by operation of law or court order (provided the Party required to
disclose Confidential Information belonging to the other Party gives the other Party as much prior
notice as is reasonably practicable and discloses only such information as it is obligated to); and

51.

 

          (b) Disclosures in connection with the performance of this Agreement to Affiliates, potential
collaborators, partners, and licensees, research collaborators, potential investment bankers,
investors, lenders, and investors, employees, consultants, or agents, each of whom prior to
disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Article 10.

The Parties acknowledge that the terms of this Agreement shall be treated as Confidential
Information of both Parties. Such terms may be disclosed by a Party to individuals or entities
covered by Section 10.3(b) above, each of whom prior to disclosure must be bound by similar
obligations of confidentiality and non-use at least equivalent in scope to those set forth in this
Article 10. In addition, a copy of this Agreement may be filed by either Party with the Securities
and Exchange Commission. In connection with any such filing, such Party shall endeavor to obtain
confidential treatment of economic and trade secret information, shall provide the other Party with
an opportunity to review and comment on such Party’s proposed redactions, and shall give due
consideration to any such comments, and shall use commercially reasonable efforts to obtain
acceptance of redactions reasonably requested by the other Party. With respect to any Third Party
License that requires Sangamo to provide to the applicable Third Party licensor a copy of this
Agreement or a summary of the terms of this Agreement, Sangamo may provide such copy or summary to
such Third Party licensor.

In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential
Information except as permitted hereunder.

     10.4 Termination of Prior Agreements. This Agreement supersedes the Secrecy Agreements
between Sangamo and DAS dated June 13, 2005, as amended, and August 15, 2002. All Information
exchanged between the Parties under such earlier agreements shall be deemed Confidential
Information of the disclosing Party and shall be subject to the terms of this Article 10.

     10.5 Publicity. The Parties agree that the public announcement of the execution of this
Agreement shall be substantially in the form of the press release attached as Exhibit E. Any other
publication, news release or other public announcement relating to this Agreement or to the
performance hereunder, shall first be reviewed and approved by both Parties; provided, however,

52.

 

that any disclosure which is required by law as advised by the disclosing Party’s counsel may
be made without the prior consent of the other Party, although the other Party shall be given
prompt notice of any such legally required disclosure and to the extent practicable shall provide
the other Party an opportunity to comment on the proposed disclosure.

     10.6 Publications. Neither Party shall publish or present the results of studies carried out
under this Agreement during the Option Period without the opportunity for prior review by the other
Party. This obligation is limited to publications or presentations that reveal that ZFP Products
or use thereof are connected with the subject matter being published; it would not apply, for
example, to publication of the results of testing a Trait if it is not revealed that the Trait is
the result of using zinc finger technology. Subject to Section 10.3, each Party agrees to provide
the other Party the opportunity to review any proposed abstracts, manuscripts or presentations
(including verbal presentations) which relate to the Field at least thirty (30) days prior to its
intended submission for publication and agrees, upon request, not to submit any such abstract or
manuscript for publication until the other Party is given a reasonable period of time to secure
patent protection for any material related to such publication which it believes to be patentable.
Both Parties understand that a reasonable commercial strategy may require delay of publication of
information or filing of patent applications. The Parties agree to review and consider delay of
publication and filing of patent applications under certain circumstances. The JSC will review
such requests and recommend subsequent action. Neither Party shall have the right to publish or
present Confidential Information of the other Party which is subject to Section 10.1.

     10.7 Patents. If disclosure of Confidential Information of one Party is necessary or useful
in prosecution of a patent application being prosecuted by the other Party, the Party to whom the
Confidential Information belongs will, on request, consider permitting use of the information and
will provide the requesting party with a decision without undue delay.

ARTICLE 11

TERM AND TERMINATION

53.

 

     11.1 Term. This Agreement shall become effective on the Effective Date and shall expire upon
the last payment obligation as provided in Sections 8.5 and 8.8-8.11, unless earlier terminated in
accordance with Section 11.2, 11.3, 11.4 or 11.6. Termination of the Subsequent Research Term
pursuant to Section 4.1 shall not constitute termination of this Agreement, although termination of
this Agreement shall result in termination of the Research Term. Termination of the Licensing
Program pursuant to Section 11.5 shall not constitute termination of this Agreement, although
termination of this Agreement shall result in termination of the Licensing Program.

     11.2 Termination after Critical Review of Research Program. This Agreement may be terminated
by DAS by written notice to Sangamo if the critical review of the Research Program pursuant to
Section 3.5(c)(x) leads to a finding that exercise of the Option is highly unlikely, provided that
such written notice is received by Sangamo prior to the end of the eighth calendar quarter of the
Initial Research Term. Such termination shall be effective as of the end of the eighth calendar
quarter of the Initial Research Term and shall have the following effect:

          (a) all licenses and rights granted to DAS under this Agreement (including without limitation
the licenses and rights set forth in Section 2.1) shall terminate;

          (b) all research licenses granted by DAS pursuant to Section 2.1(a)(ii) shall terminate;

          (c) DAS shall promptly assign to Sangamo all Technology Licenses then in effect that satisfy
Section 11.8. Sangamo may also request assignment of Technology Licenses that do not satisfy
Section 11.8, in which case DAS will also make such requested assignments. DAS shall promptly
transfer to Sangamo all Information necessary for Sangamo to take over all obligations in
Technology Licenses for which Sangamo requests assignment. Sangamo shall be entitled to receive
and keep one hundred percent (100%) of all payments made by the relevant Sublicensee after such
assignment, and Sangamo shall not have any obligation to share any portion of such payments with
DAS;

          (d) with respect to each Technology License then in effect that does not satisfy Section 11.8
and for which Sangamo has not requested assignment, DAS shall continue to

54.

 

perform all obligations under such Technology License and shall pay to Sangamo all payments
(or other consideration) made by the relevant Sublicensee after the termination effective date,
provided that DAS shall be entitled to retain, from such payments (or other consideration), an
amount equal to DAS’s documented out-of-pocket and personnel costs incurred in the course of
performing such obligations;

          (e) DAS shall assign to Sangamo DAS’s entire right, title and interest in and to the Program
Inventions and Improvements made during the Option Period (and all patents and patent applications
claiming such Program Inventions and Improvements), and the license granted to Sangamo under
Section 2.3(b) shall terminate solely with respect to such Program Inventions, Improvements,
patents, and patent applications;

          (f) DAS shall grant to Sangamo and its Affiliates a worldwide, fully paid, perpetual,
irrevocable, non-exclusive license (with the right to sublicense) to practice the DAS Improvements
and DAS Program Inventions (and any patents and patent applications claiming DAS Improvements and
DAS Program Inventions) (in each case, to the extent not assigned to Sangamo under Section
11.2(e)), for all purposes in the Field; and

          (g) DAS shall provide Sangamo with a complete and accurate list of (i) all projects in which
DAS, a DAS Affiliate, or a Sublicensee (to the extent of DAS’s knowledge) practiced the Sangamo
Technology in the Field prior to the termination effective date and (ii) all Licensed Products in
existence as of the effective date of termination.

     11.3 Termination at End of Initial Research Term. If Sangamo does not receive an Option
Exercise Notice and the fee set forth in Section 8.6 before the end of the Initial Research Term,
then this Agreement shall automatically terminate on the third anniversary of the Effective Date.
Such termination shall have the same effects as set forth in Section 11.2.

     11.4 Termination at Will. At any time after Sangamo’s receipt of the Option Exercise Notice
and the fee set forth in Section 8.6, DAS may terminate this Agreement in its entirety by providing
sixty (60) days written notice thereof to Sangamo. Such termination shall have the same effect as
set forth in Section 11.2; provided, however, that DAS may continue to make and sell any DAS
Product that was commercialized prior to the termination for so long as

55.

 

DAS continues to pay the applicable milestones and royalties due under Article 8.

     11.5 Termination of Licensing Program. At any time after the earlier of the expiration of the
last Core Patent or January 1, 2019, DAS may terminate the Licensing Program by providing sixty
(60) days written notice thereof to Sangamo. Termination of the Licensing Program pursuant to this
Section 11.5 shall not constitute termination of this Agreement but shall have the following
effects:

          (a) except as provided in this Section 11.5, the licenses and rights set forth in Sections
2.1(a)(ii), 2.1(a)(iii), 2.1(b)(i)(2), and all provisions of Article 5 shall terminate, and DAS
shall no longer have the right to grant Technology Licenses or research licenses pursuant to
Section 2.1(a)(ii), or to Manufacture ZFP Products for sale to Sublicensees;

          (b) the licenses set forth in Sections 2.1(a)(i) and 2.1(b)(ii) shall remain in effect, and
DAS’s rights and obligations with respect to DAS Products, including without limitation those
rights and obligations set forth in Article 6 and Sections 8.5 and 8.8-8.11, shall remain in
effect;

          (c) DAS shall no longer have the obligation to make minimum annual payments pursuant to
Section 8.7;

          (d) DAS shall continue to have the right pursuant to Section 2.1(b)(i)(1) to Manufacture ZFP
Products for its own use in the Field and Sangamo will remain obligated to supply ZFP Products to
DAS for DAS’s use in the Field on the terms described in Article 7;

          (e) all research licenses granted by DAS pursuant to Section 2.1(a)(ii) shall terminate;

          (f) DAS shall promptly assign to Sangamo all Technology Licenses then in effect that satisfy
Section 11.8. Sangamo may also request assignment of Technology Licenses that do not satisfy
Section 11.8, in which case DAS will also make such requested assignments. DAS shall promptly
transfer to Sangamo all Information necessary for Sangamo to take over all obligations in
Technology Licenses for which Sangamo requests assignment. Sangamo shall be entitled to receive
and keep one hundred percent (100%) of all payments made by the relevant

56.

 

Sublicensee after such assignment, and Sangamo shall not have any obligation to share any
portion of such payments with DAS; and

          (g) with respect to each Technology License then in effect that does not satisfy Section 11.8
and for which Sangamo has not requested assignment, DAS shall continue to perform all obligations
under such Technology License and shall pay to Sangamo all payments (or other consideration) made
by the relevant Sublicensee after the termination effective date, provided that DAS shall be
entitled to retain, from such payments (or other consideration), an amount equal to DAS’s
documented out-of-pocket and personnel costs incurred in the course of performing such obligations.

     11.6 Termination for Material Breach.

          (a) If either Party believes that the other Party is in material breach of this Agreement
(including without limitation any material breach of a representation or warranty made in this
Agreement), then the non-breaching Party may deliver notice of such breach to the other Party. In
such notice the non-breaching Party shall identify the actions or conduct that such Party would
consider to be an acceptable cure of such breach. For all breaches other than a failure to make a
payment set forth in Article 8, the allegedly breaching Party shall have sixty (60) days to either
cure such breach. For any breach arising from a failure to make a payment set forth in Article 8,
the allegedly breaching Party shall have thirty (30) days to cure such breach.

          (b) If the Party receiving notice of breach fails to cure such breach within the 60-day period
or 30-day period (as applicable), the Party originally delivering the notice may terminate this
Agreement upon written notice.

          (c) If a Party gives notice of termination under this Section 11.6 and the other Party
disputes in good faith whether such notice was proper, then the issue of whether this Agreement has
been terminated shall be resolved in accordance with Section 14.1. If as a result of such dispute
resolution process it is determined that the notice of termination was proper, then such
termination shall be deemed to have been effective if the breaching Party fails thereafter to cure
such breach in accordance with the determination made in the resolution process under Section 14.1
within the time period set forth in Section 11.6 for the applicable breach following

57.

 

such determination. If as a result of such dispute resolution process it is determined that
the notice of termination was improper, then no termination shall have occurred and this Agreement
shall have remained in effect.

          (d) Termination of this Agreement pursuant to this Section 11.6 shall have the following
effects:

               (i) all licenses granted to DAS under this Agreement (including without limitation the
licenses set forth in Section 2.1) shall terminate; provided, however, such licenses shall continue
solely to the extent necessary for DAS to satisfy its obligations under this Section 11.6(d);

               (ii) the rights and obligations of the Parties set forth in Sections 11.2(b), 11.2(c),
11.2(d), and 11.2(g) shall apply; and

               (iii) if terminated as a result of breach by DAS, the rights and obligations of the Parties
set forth in Sections 11.2(e) and 11.2(f) shall also apply.

     11.7 Effect of Termination; Survival.

          (a) In addition to the specific items identified as effects of termination pursuant to Section
11.2, 11.3, 11.4, or 11.6, the following provisions of this Agreement shall survive any expiration
or termination of this Agreement, regardless of cause: Sections 2.3(b) (except as set forth in
Section 11.2(e)), 2.5, 7.3 (solely with respect to the final sentence thereof), 8.15, 9.1 (other
than 9.1(a) and except to the extent that such ownership was transferred to Sangamo pursuant to
Section 11.2, 11.3, 11.4, or 11.6), 9.2(b) (but only as relates to Sections 9.4 and 9.5), 9.4 (but
only to the extent Sangamo retains an exclusive license under the DAS Improvement Patents and/or
DAS Program Patents), 9.5, 9.7 (but only to the extent Sangamo retains an exclusive license under
the DAS Improvement Patents and/or DAS Program Patents), 9.8, 11.2, 11.3, 11.4, 11.6, 11.7, 14.1,
14.2, 14.3, 14.6, 14.8, 14.16, and 14.18, and Articles 10 and 13.

          (b) In any event, termination of this Agreement shall not relieve the Parties of any liability
which accrued hereunder prior to the effective date of such termination nor preclude

58.

 

either Party from pursuing all rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain
performance of any obligation.

          (c) In the event this Agreement is terminated pursuant to Section 11.2, 11.3, 11.4, or 11.6,
DAS shall cease, and shall cause its Affiliates and sublicensees (other than Sublicensees under
Technology Licenses that continue in effect) to cease, all development and commercialization
(except commercialization explicitly permitted by Section 11.4) of DAS Products and Licensed
Products based on DAS ZFP Traits, and DAS shall not use or practice, nor shall it cause or permit
any of its Affiliates or such sublicensees to use or practice, directly or indirectly, any Sangamo
Technology, except to the extent necessary for DAS to satisfy its obligations under Section 11.2,
11.3, 11.4, or 11.6, as applicable

     11.8 Upon termination of the Agreement pursuant to Section 11.2, 11.3, 11.4, or 11.6 or
termination of the Licensing Program pursuant to Section 11.5, Sangamo will accept assignment of
Technology Licenses provided:

          (a) The only obligations pertain to Manufacturing and supplying ZFP Products;

          (b) The Technology License limits the supply obligation to reasonable quantities and timing;
and

          (c) The Technology License provides that Sangamo will be reimbursed for costs and receive a
financial return in the form of a product royalty.

ARTICLE 12

REPRESENTATIONS, WARRANTIES, AND COVENANTS

     12.1 Mutual Authority. Sangamo and DAS each represents and warrants to the other that: (i) it
has the authority and right to enter into and perform this Agreement, (ii) this Agreement is a
legal and valid obligation binding upon it and is enforceable in accordance with

59.

 

its terms, subject to applicable limitations on such enforcement based on bankruptcy laws and
other debtors’ rights, and (iii) its execution, delivery and performance of this Agreement will not
conflict in any material fashion with the terms of any other agreement or instrument to which it is
or becomes a party or by which it is or becomes bound, nor violate any law or regulation of any
court, governmental body or administrative or other agency having authority over it.

     12.2 Performance by Affiliates. The Parties recognize that each may perform some or all of
its obligations under this Agreement through Affiliates, provided, however, that each Party shall
remain responsible and be guarantor of the performance by its Affiliates and shall cause its
Affiliates to comply with the provisions of this Agreement in connection with such performance. In
particular, if any Affiliate of a Party participates in the Research Program, the Licensing
Program, or otherwise in connection with a Party’s obligations under this Agreement, (i) the
restrictions of this Agreement which apply to the activities of a Party under this Agreement shall
apply equally to the activities of such Affiliate, and (ii) the Party affiliated with such
Affiliate shall assure, and hereby guarantees, that any intellectual property developed by such
Affiliate shall be governed by the provisions of this Agreement (and subject to the licenses set
forth in Article 2) as if such intellectual property had been developed by the Party.

     12.3 Third Party Rights. Except as already disclosed, each Party represents and warrants to
the other Party that, to its knowledge as of the Effective Date, its performance of work under the
Collaboration as contemplated by this Agreement will not infringe the patent, trade secret or other
intellectual property rights of any Third Party.

     12.4 Notice of Infringement or Misappropriation. Each Party represents and warrants to the
other Party that, as of the Effective Date, it has no knowledge of infringement or misappropriation
of any alleged rights asserted by any Third Party in relation to any technology to be used in
connection with the Collaboration.

     12.5 Additional Representations, Warranties and Covenants of Sangamo.

          (a) Sangamo Know-How. With respect to the following technology developed by Sangamo, solely
to the extent that it constitutes Sangamo Know-How (it being understood that such technology also
includes inventions for which patents are pending or

60.

 

issued):

     ***

 

     ***

 

     ***

 

     ***

 

     ***

 

          (b) Sangamo represents and warrants with respect to those items below that pertain to current
facts, and covenants with respect to those items below that pertain to future actions:

               (i) that Sangamo has the full right and power to grant to DAS the licenses under such Sangamo
Know-How that are granted in Section 2.1 of this Agreement;

               (ii) that such Sangamo Know-How is proprietary to Sangamo, and the conception and development
of such Sangamo Know-How by Sangamo has not, to the knowledge of Sangamo as of the Effective Date,
constituted or involved the misappropriation of trade secrets of any Third Party;

               (iii) that Sangamo has taken commercially reasonably steps to protect those items within such
Sangamo Know-How that Sangamo has decided to maintain as trade secrets, and will continue to take
commercially reasonable steps to protect those items within such Sangamo Know-How that Sangamo
decides to maintain as trade secrets (it being understood that Sangamo may periodically re-evaluate
the value of maintaining such items as trade secrets as opposed to pursuing patent protection
therefor or permitting strategic disclosure thereof);

               (iv) that as of the Effective Date, Sangamo is not aware of any additional trade secrets or
know-how owned by Sangamo as of the Effective Date that are

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

61.

 

necessary for the design of ZFP Products for use in the Field, and if Sangamo subsequently
discovers such additional trade secrets or know-how, their existence will be disclosed to DAS;

               (v) that if additional trade secrets or know-how that are reasonably necessary or useful for
the design of ZFP Products for use in the Field are developed by Sangamo during the Research Term
and Sangamo Controls such additional trade secrets or know-how, their existence will be disclosed
to DAS;

               (vi) that the Sangamo Know-How that is reasonably necessary or useful for the design of ZFP
Products for use in the Field will be fully disclosed to DAS pursuant to Section 7.2, it being the
intent that DAS will be as enabled as Sangamo to design and develop ZFP Products for use in the
Field;

               (vii) that such Sangamo Know-How can be used to design ZFP Products for use in the Field
without infringing any patent or proprietary right (other than one licensed hereunder) of any Third
Party;

               (viii) that such Sangamo Know-How together with technology disclosed in Sangamo Patents
constitute all Sangamo Technology used by Sangamo during the Research Term for the design of ZFP
Products for use in the Field.

          (c) Sangamo Patents. With respect to the Sangamo Patents that are owned by Sangamo, Sangamo
represents and warrants with respect to those items below that pertain to current facts, and
covenants with respect to those items below that pertain to future actions:

               (i) that it has the right to grant to DAS the licenses under the Sangamo Patents that are
granted in Section 2.1 of this Agreement;

               (ii) that it is not aware, as of the Effective Date, of any written assertions of invalidity
of those Sangamo Patents that issued prior to the Effective Date, other than the opposition
to***;

               (iii) that, as of the Effective Date, it has not withheld any material

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.

62.

 

references during prosecution in the United States of those United States Sangamo Patents that
issued prior to the Effective Date;

               (iv) that the conception, development, and reduction to practice of the inventions claimed in
the Sangamo Patents has not, to the knowledge of Sangamo as of the Effective Date, constituted or
involved the misappropriation or infringement of trade secrets or other intellectual property of
any Third Party;

               (v) that, to the knowledge of Sangamo as of the Effective Date, there are no claims,
judgments, or settlements relating to the Sangamo Patents to be paid by Sangamo;

               (vi) that, to the knowledge of Sangamo as of the Effective Date, no pending claim has been
brought by any person or entity alleging that the Sangamo Patents conflict or interfere with any
intellectual property or proprietary right of any Third Party;

               (vii) that Sangamo is not aware, as of the Effective Date, of any infringement of the Sangamo
Patents by a Third Party, other than those disclosed to DAS in response to its Due Diligence
Requests.

          (d) Third Party Licenses. With respect to the Third Party Licenses set forth in Exhibit C as
of the Effective Date, Sangamo represents and warrants with respect to those items below that
pertain to current facts, and covenants with respect to those items below that pertain to future
actions:

               (i) that, to its knowledge as of the Effective Date, it is not in material breach of its
obligations thereunder as of the Effective Date and it will continue to perform all of its
obligations thereunder that, if not performed, would have a material adverse effect on DAS’s rights
under this Agreement,

               (ii) that if it is unable to fulfill such obligations at any time, it will notify DAS as soon
as practicable;

               (iii) that it will not voluntarily terminate any Third Party License without the consent of
DAS, such consent not to be unreasonably withheld, and it will use commercially reasonable efforts
to cure any material breach of any Third Party License during

63.

 

the life of this Agreement;

               (iv) that Sangamo has the right to grant the sublicenses thereunder to DAS that are granted in
Section 2.1 of this Agreement;

               (v) that, if DAS cannot grant further sublicenses under a particular Third Party License, then
at DAS’s request in conjunction with DAS’s entry into a Technology License, Sangamo will grant a
sublicense (within 30 days) under such Third Party License to the Sublicensee for such Technology
License on terms that are consistent with such Technology License and Sections 2.1(a)(iii), 2.1(c),
2.6, 8.11 and Exhibit D of this Agreement and that do not provide Sangamo with greater compensation
than it would have received had such sublicense been granted by DAS pursuant to such Technology
License;

               (vi) that the conception, development, and reduction to practice of the technology licensed in
the Field under Third Party Licenses is not known by Sangamo as of the Effective Date to have
constituted or involved the misappropriation or infringement of trade secrets or other intellectual
property of any Third Party;

     12.6 Future Discussion. On written request by DAS, Sangamo will discuss with DAS an
appropriate accommodation (which may involve a reduction in certain future payments owed to Sangamo
under this Agreement) to reflect the reduced commercial value of the licenses granted to DAS under
this Agreement as a result of:

          (a) failure of Sangamo to consent to DAS’s request, pursuant to Section 9.6(b)(ii), to have
the right to attempt to resolve serious and sustained Infringement of Core Patents after Sangamo’s
failure to resolve such Infringement or initiate or defend a suit with respect thereto within one
hundred twenty (120) days of the notice set forth in Section 9.6(a), wherein such Infringement has
a material adverse effect on DAS’s rights under this Agreement;

          (b) activity in the Field by unlicensed Third Parties that does not constitute Infringement
and that has a material adverse effect on DAS’s ability to enter into Technology Licenses; or

          (c) issuance of a Necessary Claim, where “Necessary Claim” means a claim

64.

 

of an issued United States patent with a patent issuance date after the Effective Date that
(i) is not owned, controlled or licensed by Sangamo within six (6) months of such patent issuance
date and (ii) is necessarily infringed by DAS’s activities in the Field, wherein a patent claim is
necessarily infringed when no technically and commercially reasonable non-infringing alternative
for practicing activities within the Field exists or can be developed, and DAS’s inability to
practice such activities without infringement has a material adverse effect on DAS’s rights under
this Agreement.

          (d) If the Parties cannot agree on applicability of this Section 12.6, or on the appropriate
accommodation, the dispute will be referred, upon written notice by either Party, to the CEOs.
Within twenty (20) days after such notice, the CEOs shall meet for attempted resolution by good
faith negotiations. If the CEOs are unable to resolve such dispute within thirty (30) days of
their first meeting for such negotiations, then either Party may seek to have such dispute finally
settled by a single arbitrator under the rules of the American Arbitration Association applicable
to expedited arbitrations.

ARTICLE 13

INDEMNIFICATION

     13.1 Mutual Indemnification. Subject to Section 13.3, each Party hereby agrees to indemnify,
defend and hold the other Party, its Affiliates, its licensees, and its and their officers,
directors, employees, consultants, contractors, sublicensees and agents (collectively, the
“Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third
Party claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by such
Indemnitee as to any such Claim (as defined in this Section 13.1) until the indemnifying Party has
acknowledged that it will provide indemnification hereunder with respect to such Claim as provided
below (collectively, “Damages”) resulting from claims, suits, proceedings or causes of action
(“Claims”) brought by such Third Party against such Indemnitee based on: (a) a breach of warranty
by the indemnifying Party contained in this Agreement; (b) breach of this Agreement or applicable
law by such indemnifying Party; (c) negligence or willful misconduct

65.

 

of a Party, its Affiliates or (sub)licensees, or their respective employees, contractors or
agents in the performance of this Agreement; and/or (d) breach of a contractual or fiduciary
obligation owed by it to a Third Party (including without limitation misappropriation of trade
secrets).

     13.2 Additional Indemnification by DAS. Subject to Section 13.3, DAS hereby agrees to
indemnify, defend and hold harmless Sangamo and its directors, agents and employees from and
against any and all suits, claims, actions, demands, liabilities, expenses and/or loss, including
reasonable legal expenses and reasonable attorneys’ fees (“Losses”) resulting directly or
indirectly from (a) the manufacture, use, handling, storage, marketing, sale or other disposition
of DAS Products or Licensed Products by DAS, its Affiliates, agents or sublicensees (including
Sublicensees); and (b) the manufacture, use, handling, storage, marketing, sale or other
disposition of ZFP Products by DAS or its Affiliates or agents. Such indemnity obligation shall
not apply to the extent such Losses result from (a) a breach of warranty by Sangamo contained in
this Agreement; (b) breach of this Agreement or applicable law by Sangamo; (c) negligence or
willful misconduct by Sangamo, its Affiliates or (sub)licensees, or their respective employees,
contractors or agents in the performance of this Agreement; and/or (d) breach of a contractual or
fiduciary obligation owed by Sangamo to a Third Party (including without limitation
misappropriation of trade secrets).

     13.3 Conditions to Indemnification. As used herein, “Indemnitee” shall mean a party entitled
to indemnification under the terms of Section 13.1 or 13.2. It shall be a condition precedent to
an Indemnitee’s right to seek indemnification under such Section 13.1 or 13.2:

          (a) shall inform the indemnifying Party under such applicable Section of a Claim as soon as
reasonably practicable after it receives notice of the Claim;

          (b) shall, if the indemnifying Party acknowledges that such Claim falls within the scope of
its indemnification obligations hereunder, permit the indemnifying Party to assume direction and
control of the defense, litigation, settlement, appeal or other disposition of the Claim (including
the right to settle the claim solely for monetary consideration); provided, that the indemnifying
Party shall seek the prior written consent (not to be unreasonably withheld or delayed) of any such
Indemnitee as to any settlement which would materially diminish or materially adversely affect the
scope, exclusivity or duration of any Patents licensed under this

66.

 

Agreement, would require any payment by such Indemnitee, would require an admission of legal
wrongdoing in any way on the part of an Indemnitee, or would effect an amendment of this Agreement;
and

          (c) shall fully cooperate (including providing access to and copies of pertinent records and
making available for testimony relevant individuals subject to its control) as reasonably requested
by, and at the expense of, the indemnifying Party in the defense of the Claim.

Provided that an Indemnitee has complied with the foregoing, the indemnifying Party shall provide
attorneys reasonably acceptable to the Indemnitee to defend against any such Claim. Subject to the
foregoing, an Indemnitee may participate in any proceedings involving such Claim using attorneys of
its/his/her choice and at its/his/her expense. In no event may an Indemnitee settle or compromise
any Claim for which it/he/she intends to seek indemnification from the indemnifying Party hereunder
without the prior written consent of the indemnifying Party, or the indemnification provided under
such Section 13.1 or 13.2 as to such Claim shall be null and void.

     13.4 Limitation of Liability. EXCEPT FOR AMOUNTS PAYABLE TO THIRD PARTIES BY A PARTY FOR
WHICH IT SEEKS REIMBURSEMENT OR INDEMNIFICATION PROTECTION FROM THE OTHER PARTY PURSUANT TO
SECTIONS 13.1 AND 13.2, AND EXCEPT FOR BREACH OF SECTION 10.1 HEREOF, IN NO EVENT SHALL EITHER
PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY FOR
ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON
A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE,
ARISING OUT OF THIS AGREEMENT, UNLESS SUCH DAMAGES ARE DUE TO THE GROSS NEGLIGENCE OR WILLFUL
MISCONDUCT OF THE LIABLE PARTY. For clarification, the foregoing sentence shall not be interpreted
to limit or to expand the express rights specifically granted in the sections of this Agreement.

     13.5 Collaboration Disclaimer. EXCEPT AS PROVIDED IN ARTICLE 12

67.

 

ABOVE, DAS EXPRESSLY DISCLAIMS ANY AND ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES WITH RESPECT TO
ANY RESEARCH RESULTS, DATA, OR INVENTIONS (AND ANY PATENT RIGHTS OBTAINED THEREON) IDENTIFIED, MADE
OR GENERATED BY DAS AS PART OF THE COLLABORATION OR OTHERWISE MADE AVAILABLE TO SANGAMO PURSUANT TO
THE TERMS OF THIS AGREEMENT. EXCEPT AS PROVIDED IN ARTICLE 12 ABOVE, SANGAMO EXPRESSLY DISCLAIMS
ANY AND ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE
WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES WITH RESPECT TO ANY RESEARCH RESULTS, ZFP PRODUCTS,
DATA, OR INVENTIONS (AND ANY PATENT RIGHTS OBTAINED THEREON) IDENTIFIED, MADE OR GENERATED BY
SANGAMO AS PART OF THE COLLABORATION OR OTHERWISE MADE AVAILABLE TO DAS PURSUANT TO THE TERMS OF
THIS AGREEMENT.

ARTICLE 14

MISCELLANEOUS

     14.1 Dispute Resolution. In the event of any controversy or claim arising out of, relating to
or in connection with any provision of this Agreement, other than a dispute addressed in Section
12.6(d) or 14.3 or issues unresolved by the JSC that are submitted for resolution as provided in
Section 3.5(d), the Parties shall try to settle their differences amicably between themselves
first, by referring the disputed matter to the Senior Vice President of Business Development of
Sangamo and the Vice President of Research of DAS (or if either foregoing position does not exist
at such time, the closest successor in title to such position) (the “Representatives”) and, if not
resolved by such Representatives, by referring the disputed matter to the CEOs of the Parties or
their designees. Either Party may initiate such informal dispute

68.

 

resolution by sending written notice of the dispute to the other Party, and, within twenty
(20) days after such notice, the Representatives shall meet for attempted resolution by good faith
negotiations. If the Representatives are unable to resolve such dispute within thirty (30) days of
their first meeting for such negotiations, then the CEOs shall meet within twenty (20) days
thereafter for attempted resolution by good faith negotiations. If the CEOs are unable to resolve
such dispute within thirty (30) days of their first meeting for such negotiations, either Party may
seek to have such dispute resolved in any United States federal or state court of competent
jurisdiction and appropriate venue. To the extent permitted by law, the Party that seeks such
judicial resolution hereby consents to the other Party’s forum of choice, provided the choice is
limited to California, Indiana, or Delaware.

     14.2 Governing Law. Resolution of all disputes arising out of or related to this Agreement or
the performance, enforcement, breach or termination of this Agreement and any remedies relating
thereto, shall be governed by and construed under the substantive laws of the State of Delaware, as
applied to agreements executed and performed entirely in the State of California by residents of
the State of Delaware, without regard to conflicts of law rules that would cause the application of
the laws of another jurisdiction.

     14.3 Patents and Trademarks. Any dispute, controversy or claim relating to the scope,
validity, enforceability or infringement of any patents or trademark rights shall be submitted to a
court of competent jurisdiction in the territory in which such patents or trademark rights were
granted or arose.

     14.4 Entire Agreement; Amendment. This Agreement set forth the complete, final and exclusive
agreement and all the covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto and supersedes and terminates all prior agreements and
understandings between the Parties. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between the Parties other
than as are set forth herein and therein. No subsequent alteration, amendment, change or addition
to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an
authorized officer of each Party.

     14.5 Export Control. This Agreement is made subject to any restrictions concerning

69.

 

the export of products or technical information from the United States of America or other
countries which may be imposed upon or related to Sangamo or DAS from time to time. Each Party
agrees that it will not export, directly or indirectly, any technical information acquired from the
other Party under this Agreement or any products using such technical information to a location or
in a manner that at the time of export requires an export license or other governmental approval,
without first obtaining the written consent to do so from the appropriate agency or other
governmental entity.

     14.6 Bankruptcy

          (a) All rights and licenses granted under or pursuant to this Agreement, including amendments
hereto, by each Party to the other Party are, for all purposes of Section 365(n) of Title 11 of the
United States Code (“Title 11”), licenses of rights to intellectual property as defined in Title
11. Each Party agrees during the term of this Agreement to create and maintain current copies or,
if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent
feasible, of all such intellectual property. If a case is commenced by or against either Party
(the “Bankrupt Party”) under Title 11, then, unless and until this Agreement is rejected as
provided in Title 11, the Bankrupt Party (in any capacity, including debtor-in-possession) and its
successors and assigns (including, without limitation, a Title 11 Trustee) shall, at the election
of the Bankrupt Party made within sixty (60) days after the commencement of the case (or, if no
such election is made, immediately upon the request of the non-Bankrupt Party) either (i) perform
all of the obligations provided in this Agreement to be performed by the Bankrupt Party including,
where applicable and without limitation, providing to the non-Bankrupt Party portions of such
intellectual property (including embodiments thereof) held by the Bankrupt Party and such
successors and assigns or otherwise available to them or (ii) provide to the non-Bankrupt Party all
such intellectual property (including all embodiments thereof) held by the Bankrupt Party and such
successors and assigns or otherwise available to them.

          (b) If a Title 11 case is commenced by or against the Bankrupt Party and this Agreement is
rejected as provided in Title 11 and the non-Bankrupt Party elects to retain its rights hereunder
as provided in Title 11, then the Bankrupt Party (in any capacity, including

70.

 

debtor-in-possession) and its successors and assigns (including, without limitations, a Title
11 Trustee) shall provide to the non-Bankrupt Party all such intellectual property (including all
embodiments thereof) held by the Bankrupt Party and such successors and assigns or otherwise
available to them immediately upon the non-Bankrupt Party’s written request therefor. Whenever the
Bankrupt Party or any of its successors or assigns provides to the non-Bankrupt Party any of the
intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 14.6,
the non-Bankrupt Party shall have the right to perform the obligations of the Bankrupt Party
hereunder with respect to such intellectual property, but neither such provision nor such
performance by the non-Bankrupt Party shall release the Bankrupt Party from any such obligation or
liability for failing to perform it.

          (c) All rights, powers and remedies of the non-Bankrupt Party provided herein are in addition
to and not in substitution for any and all other rights, powers and remedies now or hereafter
existing at law or in equity (including, without limitation, Title 11) in the event of the
commencement of a Title 11 case by or against the Bankrupt Party. The non-Bankrupt Party, in
addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise
all other such rights and powers and resort to all other such remedies as may now or hereafter
exist at law or in equity (including, without limitation, under Title 11) in such event. The
Parties agree that they intend the foregoing non-Bankrupt Party rights to extend to the maximum
extent permitted by law and any provisions of applicable contracts with Third Parties, including
without limitation for purposes of Title 11, (i) the right of access to any intellectual property
(including all embodiments thereof) of the Bankrupt Party or any Third Party with whom the Bankrupt
Party contracts to perform an obligation of the Bankrupt Party under this Agreement, and, in the
case of the Third Party, which is necessary for the development, registration and manufacture of
Licensed Products and (ii) the right to contract directly with any Third Party described in (i) in
this sentence to complete the contracted work. Any intellectual property provided pursuant to the
provisions of this Section 14.6 shall be subject to the licenses set forth elsewhere in this
Agreement and the payment obligations of this Agreement, which shall be deemed to be royalties for
purposes of Title 11.

     14.7 Force Majeure. Both Parties shall be excused from the performance of their obligations
under this Agreement to the extent that such performance is prevented by force

71.

 

majeure and the nonperforming Party promptly provides notice of the prevention to the other
Party. Such excuse shall be continued so long as the condition constituting force majeure
continues and the nonperforming Party takes reasonable efforts to remove the condition. For
purposes of this Agreement, “force majeure” shall mean conditions beyond the control of the
Parties, including without limitation, an act of God, voluntary or involuntary compliance with any
regulation, law or order of any government, war, terrorism, civil commotion, labor strike or
lock-out, epidemic, failure or default of public utilities or common carriers, destruction of
production facilities or materials by fire, earthquake, storm or like catastrophe; provided,
however, the payment of invoices due and owing hereunder shall not be delayed by the payer because
of a force majeure affecting the payer.

     14.8 Notices. Any notice required or permitted to be given under this Agreement shall be in
writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently
given for all purposes if mailed by first class certified or registered mail, postage prepaid,
express delivery service or personally delivered. Unless otherwise specified in writing, the
mailing addresses of the Parties shall be as described below.

	 	 	 	 	 
	 

	 	For Sangamo:
	 	Sangamo BioSciences, Inc.
	 

	 	 	 	Point Richmond Tech Center
	 

	 	 	 	501 Canal Boulevard, Suite A100
	 

	 	 	 	Richmond, California 94804
	 

	 	 	 	Attention: Chief Executive Officer
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Cooley Godward LLP
	 

	 	 	 	Five Palo Alto Square
	 

	 	 	 	3000 El Camino Real
	 

	 	 	 	Palo Alto, CA 94306
	 

	 	 	 	Attention: Marya A. Postner, Esq.
	 
	 	 	 	 
	 

	 	For DAS:
	 	Dow AgroSciences LLC
	 

	 	 	 	9330 Zionsville Road
	 

	 	 	 	Indianapolis, Indiana 46268
	 

	 	 	 	Attention: General Counsel
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Vice President, Plant Genetics & Biotechnology

     14.9 Maintenance of Records. Each Party shall keep and maintain all records required by law
or regulation with respect to Licensed Products and shall make copies of such records available to
the other Party upon request.

72.

 

     14.10 United States Dollars. References in this Agreement to “dollars” or “$” shall mean the
legal tender of the United States of America.

     14.11 No Strict Construction. This Agreement has been prepared jointly and shall not be
strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have authored the
ambiguous provision.

     14.12 Assignment. Neither Party may assign or transfer this Agreement or any rights or
obligations hereunder without the prior written consent of the other, except a Party may make such
an assignment without the other Party’s consent to an Affiliate or to a Third Party successor to
substantially all of the business of such Party to which this Agreement relates, whether in a
merger, sale of stock, sale of assets or other transaction; provided that any such permitted
successor or assignee of rights and/or obligations hereunder is obligated, by reason of operation
of law or pursuant to a written agreement with the other Party, to assume performance of this
Agreement or such rights and/or obligations; and provided, further, that if assigned to an
Affiliate, the assigning Party shall remain jointly and severally responsible for the performance
of this Agreement by such Affiliate. Any permitted assignment shall be binding on the successors
of the assigning Party. Any assignment or attempted assignment by either Party in violation of the
terms of this Section 14.12 shall be null and void and of no legal effect.

     14.13 Electronic Data Interchange. If both Parties elect to facilitate business activities
hereunder by electronically sending and receiving data in agreed formats (also referred to as
Electronic Data Interchange or “EDI”) in substitution for conventional paper-based documents, the
terms and conditions of this Agreement shall apply to such EDI activities.

     14.14 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     14.15 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry
out the purposes and intent of this Agreement.

73.

 

     14.16 Severability. If any one or more of the provisions of this Agreement is held to be
invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is
taken, the provision shall be considered severed from this Agreement and shall not serve to
invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by the Parties when entering this Agreement may be realized.

     14.17 Headings. The headings for each article and section in this Agreement have been
inserted for convenience of reference only and are not intended to limit or expand on the meaning
of the language contained in the particular article or section.

     14.18 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver
as to a particular default or other matter shall not constitute a waiver of such Party’s rights to
the future enforcement of its rights under this Agreement, excepting only as to an express written
and signed waiver as to a particular matter for a particular period of time.

[Rest of Page Intentionally Left Blank]

74.

 

     In Witness Whereof, the Parties have executed this Research and Commercial License
Option Agreement in duplicate originals by their proper officers as of the date and year first
above written.

	 	 	 	 	 	 	 	 	 
	Sangamo BioSciences, Inc.	 	Dow AgroSciences LLC	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Edward Lanphier
 

	 	By:
	 	/s/ Daniel R. Kittle
 

	 	  
	 
	 	 	 	 	 	 	 	 
	Title:

	 	President and CEO
 

	 	Title:
	 	 Vice President, Research and Development
 

	 	  

75.

 

Exhibit A

Sangamo Patents

Title: ***

Inventor: ***

Owner: ***

Chain of Title: ***

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

76.

 

Exhibit B

Core Patents

Title: ***

Inventor: ***

Owner: ***

Chain of Title: ***

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

77.

 

Exhibit C

Third Party Licenses

     Patent License Agreement by and between *** and Sangamo Biosciences, Inc. dated
*** and amended***;***; and *** (the
“***Agreement”).

     License Agreement by and between ***and Sangamo Biosciences, Inc. dated
*** and amended *** (the “***Agreement”).

     License Agreement by and between *** and Sangamo Biosciences, Inc. dated
***and amended ***and *** (the “***Agreement”).

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

78.

 

Exhibit D

Certain Terms of Third Party Licenses

     DAS hereby agrees to comply, and to cause its applicable sublicensees to comply, with the
following referenced provisions of the *** Agreement: Articles 2, 5, 7, 8, 9, 10, 12,
13 and 15. Such provisions are hereby incorporated by reference into this Agreement and are
binding upon DAS and such sublicensees as if they were parties to the *** Agreement.

     DAS hereby agrees to comply, and to cause its applicable sublicensees to comply, with the
following referenced provisions of the *** Agreement: Articles II, VIII, IX, X, XIII
and XV and Paragraphs 5.1 and 5.2. A copy of such provisions is attached to this Agreement as
Exhibit F, and such provisions and are binding upon DAS and such sublicensees as if they were
parties to the *** Agreement.

     DAS hereby agrees to comply with the following referenced provisions of the ***
Agreement: Sections 7.7 and 8.4 and Article 12. Such provisions and are binding upon DAS as if it
were a party to the *** Agreement. DAS hereby acknowledges that, pursuant to Section
2.3 of the *** Agreement, DAS does not have the right to grant sublicenses under the
intellectual property licensed to Sangamo pursuant to the *** Agreement.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

79.

 

Exhibit E

Press Release

80.

 

Exhibit F

Copy of Selected Provisions of *** Agreement

ARTICLE II – GRANT

     2.1 *** hereby grants to LICENSEE the exclusive worldwide right and license to
make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes,
including the right to grant sublicenses, subject to 35USC200-211 and the regulations promulgated
thereunder, to the end of the term for which the Patent Rights are granted by the applicable
governmental authority, unless sooner terminated as hereinafter provided (the “Term”). ***
reserves the non-transferable royalty-free right to practice the subject matter of any claim
within the Patent Rights for its own internal purposes. If *** leaves ***, he
shall have the non-transferable, royalty-free right to practice any claim within the Patent Rights
for his own academic purposes.

     2.2 In order to establish a period of exclusivity for LICENSEE, *** hereby agrees
that it shall not grant any other license to make, have made, use, lease or sell Licensed Products
or to practice Licensed Processes except for its internal research activities during the period of
time (the “Exclusive Period”) commencing with the Effective Date of this Agreement and terminating
with expiration of the last-to-expire patent licensed under this Agreement, unless converted
earlier to a nonexclusive license pursuant to Paragraph 4.4 hereof or pursuant to a requirement by
the United States Government in accordance with 35USC200-211.

     2.3 LICENSEE shall have the right to sublicense all or any part of this license. LICENSEE
agrees that any sublicenses granted by it shall provide that the obligations to *** of
Articles II, VIII, IX, X, XIII, XV, and Paragraphs 5.1 and 5.2 of this Agreement shall be binding
upon the sublicensees as if it were a party to this Agreement. LICENSEE further agrees to attach
copies of these Articles to sublicense agreements.

     2.4 LICENSEE agrees to forward to *** a copy of any and all fully executed
sublicense agreements, and further agrees to forward to ***, quarterly, pursuant to
Paragraph 5.2 a copy of such reports received by LICENSEE from its sublicensees during the
preceding twelve (12) month period under the sublicenses as shall be pertinent to a royalty
accounting under said sublicense agreements.

     2.5 Subject to Sections 2.6, 2.7 and 15.7 below, the license granted hereunder shall not be
construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any
technology not specifically set forth in Appendix A, Appendix B, Appendix C, and Appendix D hereof.

     2.6 *** hereby also grants to LICENSEE a right of first negotiation at then
commercially reasonable terms, to obtain an exclusive license to any Inventions, as previously
defined, developed during the term of this Agreement and any extension thereof and pursuant to

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

81.

 

any
Research Agreement between the parties hereto (Appendix D). *** shall promptly give
LICENSEE written notice of any such Inventions, as defined, and LICENSEE shall have one hundred and
twenty (120) days from the date of receipt of such notice to give *** written notice of
its intent to exercise such option and complete negotiations. *** shall not negotiate
with any third party regarding these Inventions during the period of LICENSEE’S right to negotiate.
During the term of this Agreement and any extension thereof, *** shall be free to pursue
any scientific investigations of his choice through collaboration with colleagues. Should any such
collaboration involve a Licensed Product or Licensed Process, *** will take the
initiative of promptly communicating with these colleagues for the purpose of using its reasonable
best efforts to have such colleagues agree to be bound by the terms of this Agreement with regard
to Licensed Products and Licensed Processes.

     2.7 Appendix B attached hereto contains ideas conceived by *** for developing
laboratory reagents, diagnostics, and pharmaceuticals relating to chimeric restriction
endonucleases. *** shall give written notice of any Invention resulting under the
Advanced Technology Program within sixty (60) days of the completion of the funding of such
program. Any Invention resulting in whole or in part from said ideas which are made pursuant to an
award under the Advanced Technology Program where a grant application was filed on March 29, 1995
(Appendix C) shall be assigned to LICENSEE pursuant to Section 15.7 below and *** will
be named as sole inventor unless another individual makes a creative input to said Invention.
LICENSEE shall have the first right of negotiation, under then commercially reasonable terms, to
obtain an exclusive, royalty-bearing license under any Invention resulting from said ideas in
Appendix B made by *** with funding from a source other than the Advanced Technology
Program grant.

PARAGRAPHS 5.1 AND 5.2

     5.1 LICENSEE shall keep full, true and accurate books of account containing all particulars
that may be necessary for the purpose of showing the amounts payable to *** hereunder.
Said books of account shall be kept at LICENSEE’s principal place of business or the principal
place of business of the appropriate Division of LICENSEE to which this Agreement relates. Said
books and the supporting data shall be open at all reasonable times for five (5) years following
the end of the calendar year to which they pertain, to the inspection of *** or its
agents for the purpose of verifying LICENSEE’s royalty statement or compliance in other respects
with this Agreement.

     5.2 Commencing with the first commercial sale of a Licensed Product, LICENSEE, within sixty
(60) days after March 31, June 30, September 30 and December 31, of each year, shall deliver to
*** true and accurate reports, giving such particulars of the business conducted by
LICENSEE, its Subsidiaries and its sublicensees during the preceding three-month period under this
Agreement as shall be pertinent to a royalty accounting hereunder. These shall include at least the
following:

     (a) All Licensed Products manufactured and sold.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

82.

 

     (b) Total billings for Licensed Products sold.

     (c) Accounting for all Licensed Processes used or sold.

     (d) Deductions applicable as provided in Paragraph 1.6.

     (e) Total royalties due.

     (f) Names and addresses of all sublicensees of LICENSEE.

Where reasonably practical, LICENSEE shall, to the best of its knowledge, subcategorize the
Licensed Products sold so as to assign the royalties paid to individual patent(s) of Appendix A.
Such subcategorization shall be for *** administrative purposes only and shall in no way
affect any obligations of any part or the amounts of royalties to be paid under this Agreement.
Until there has been a first commercial sale of a Licensed Product, the LICENSEE shall give an
annual report of LICENSEE’s efforts to achieve a first commercial sale.

ARTICLE VIII — LIABILITY

     8.1 Inasmuch as *** will not, under the provisions of this Agreement or otherwise,
have control over the manner in which LICENSEE, or its Subsidiaries or its agents or its
sublicensees or those operating for its account, or third parties who purchase Licensed Products
from any of the foregoing entities, practice any invention encompassed by the license granted
herein, LICENSEE shall defend and hold ***, it trustees, officers, employees, students,
and affiliates harmless as against any judgments, fees, expenses or other costs (including
reasonable attorneys’ fees) arising from or incidental to any product liability or other lawsuit
brought as a consequence of the practice of said invention by any of the foregoing entities,
whether or not *** is named as party defendant in any such lawsuit. LICENSEE shall have
the right to defend such a product liability lawsuit with counsel of its own choosing and
*** will cooperate in the defense of such action at LICENSEE’s expense. Practice of the
Invention encompassed by the license granted herein by a Subsidiary or an agent or a sublicensee,
or a third party on behalf of or for the account of LICENSEE or by a third party who purchases
Licensed Products from any of the foregoing shall be considered LICENSEE’s practice of said
invention for purposes of this Paragraph 8.1. The provisions of this Paragraph 8.1 shall survive
termination of this Agreement.

     8.2 LICENSEE shall maintain or cause to be maintained, prior to the first planned use of
Licensed Products or Licensed Processes in humans, product liability insurance or other protection
reasonably acceptable to *** which shall protect LICENSEE and *** in regard
to events covered by Paragraph 8.1 above. LICENSEE will disclose to *** the amount and
kind of product liability insurance it obtains, will give *** a copy of the certificate
of insurance, and will increase or change the kind of insurance at the reasonable request of
***, provided such insurance is available to LICENSEE at commercially reasonable rates.

     8.3 Except as otherwise expressly set forth in this Agreement, *** makes no
representations and extend no warranties of any kind, either express or implied, including but not

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

83.

 

limited to warranties of merchantability, fitness for a particular purpose, and validity of Patent
Rights claims, issued or pending.

     8.4 No liability under this Agreement shall result to a party from delay in performance caused
by force majeure, that is, circumstances beyond the reasonable control of the party affected
thereby, including, without limitation, acts of God, earthquake, fire, flood, war, government
regulations, labor unrest, or shortage of or an inability to obtain material or equipment.

ARTICLE IX — EXPORT CONTROLS

     It is understood that *** is subject to United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes and other
commodities (including the Arms Export Control Act, as amended and the Export Administration Act of
1979), and that their obligations hereunder are contingent on compliance with applicable United
States export laws and regulations. The transfer of certain technical data and commodities may
require a license from the cognizant agency of the United States Government and/or written
assurances by LICENSEE that LICENSEE shall not export data or commodities to certain foreign
countries without prior approval of such agency. *** neither represents that a license
shall not be required nor that, if required, it shall be issued.

ARTICLE X — NON-USE OF NAMES

     LICENSEE shall not use the name of ***, nor any of its employees, or any adaptation
thereof, in any advertising, promotional or sales literature without prior written consent obtained
from *** in each case, except that LICENSEE may state that it is licensed by *** under
one or more of the patents and/or applications comprising the Patent Rights.

ARTICLE XIII — TERMINATION

     13.1 This Agreement shall terminate if LICENSEE dissolves, unless this Agreement has been
assigned prior to the date of dissolution.

     13.2 Should LICENSEE fail to pay *** royalties due and payable hereunder,
*** shall have the right to terminate this Agreement on sixty (60) days’ written notice,
unless LICENSEE shall pay *** within the sixty (60) day period, all such royalties and
interest due and payable. Upon the expiration of the sixty (60) day period, if LICENSEE shall not
have paid all such royalties and interest due and payable, the rights, privileges and license
granted hereunder shall terminate.

     13.3 Upon any material breach or default of this Agreement by LICENSEE other than those
occurrences set out in Paragraphs 13.1 and 13.2 hereinabove, which shall always take precedence in
that order over any material breach or default referred to in this Paragraph 13.3, ***
shall have the right to terminate this Agreement and the rights, privileges and license granted
hereunder by giving ninety (90) days’ notice to LICENSEE. Such termination shall become

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

84.

 

effective
unless LICENSEE shall have cured any such breach or default prior to the expiration of the ninety
(90) day period.

     13.4 LICENSEE shall have the right to terminate this Agreement at any time on six (6) months’
notice to *** and upon payment of all amounts due***.

     13.5 Upon termination of this Agreement for any reason, nothing herein shall be construed to
release either party from any obligation that matured prior to the effective date of such
termination. LICENSEE and any Subsidiary and sublicensee thereof may, however, after the effective
date of such termination, sell all Licensed Products, and complete Licensed Products in the process
of manufacture at the time of such termination and sell the same, provided that LICENSEE shall pay
to *** the royalties thereon as required by Article IV of this Agreement and shall
submit the reports required by Article V hereof on the sales of Licensed Products.

     13.6 Upon termination of this Agreement for any reason during the Exclusive Period, any
sublicensee not then in default shall have the right to seek a license from *** under
the same terms and conditions as set forth hereunder.

     13.7 The provisions of Paragraph 8.1, Article IX and Article X, Paragraph 4.5 and Paragraph
6.6, shall survive termination of this Agreement. (as amended on June 1, 1998)

ARTICLE XV — MISCELLANEOUS PROVISIONS

     15.1 This Agreement shall be construed, governed, interpreted and applied in accordance with
the laws of the State of Maryland, U.S.A., except that questions affecting the validity,
construction and effect of any patent licensed hereunder, shall be determined by the law of the
country in which the patent was granted.

     15.2 The parties hereto acknowledge that this Agreement sets forth the entire Agreement and
understanding of the parties hereto as to the subject matter hereof, and shall not be subject to
any change or modification except by the execution of a written instrument subscribed to by the
parties hereto.

     15.3 The provisions of this Agreement are severable, and in the event that any provisions of
this Agreement shall be determined to be invalid or unenforceable under any controlling body of the
law, such invalidity or unenforceability shall not in any way affect the validity or enforceability
of the remaining provisions hereof.

     15.4 LICENSEE agrees to mark the Licensed Products sold in the United States with all
applicable United States patent numbers. All Licensed Products shipped to or sold in other
countries shall be marked in such a manner as to conform with the patent laws and practice of the
country of manufacture or sale.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

85.

 

     15.5 The failure of any party to assert a right hereunder or to insist upon compliance with
any term or condition of this Agreement shall not constitute a waiver of that right or excuse a
similar subsequent failure to perform any such term or condition by the other party.

     15.6 Claims, disputes, or controversies concerning the validity, construction, or effect of
any patent licensed hereunder shall be resolved in any court having jurisdiction thereof.

     15.7 A grant application under the Advanced Technology Program was filed on March 29, 1995
(Appendix C). If a grant is awarded, any Invention made pursuant thereto where an investigator at
*** is the sole inventor or a coinventor shall be assigned to LICENSEE. Such Invention
shall be assigned hereunder and shall thereafter fall within the definition of Patent Rights and
therefore shall be subject to Sections 3.2, 3.3 and 3.4 hereof and to the royalty payments required
by Sections 4.1(c)(i), 4.1(d) and 4.4 hereof as part of the rights licensed hereunder.

     15.8 With respect to *** LICENSEE hereby acknowledges and agrees that
*** is the sole inventor of this property. (as amended on June 1, 1998)

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Commission pursuant to a request for Confidential Treatment.

86.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]